Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2021 | Nov. 12, 2021 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Sep. 30, 2021 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q3 | |
Current Fiscal Year End Date | --12-31 | |
Entity Registrant Name | RANI THERAPEUTICS HOLDINGS, INC. | |
Entity Central Index Key | 0001856725 | |
Entity File Number | 001-40672 | |
Entity Tax Identification Number | 86-3114789 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 2051 Ringwood Avenue | |
Entity Address, City or Town | San Jose | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 95131 | |
City Area Code | 408 | |
Local Phone Number | 457-3700 | |
Title of 12(b) Security | Class A common stock, par value $0.0001 per share | |
Trading Symbol | RANI | |
Security Exchange Name | NASDAQ | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Common Class A [Member] | ||
Document Information [Line Items] | ||
Entity Common Stock, Shares Outstanding | 19,711,874 | |
Common Class B [Member] | ||
Document Information [Line Items] | ||
Entity Common Stock, Shares Outstanding | 29,290,391 | |
Common Class C [Member] | ||
Document Information [Line Items] | ||
Entity Common Stock, Shares Outstanding | 0 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 129,743 | $ 73,058 |
Related party note receivable | 0 | 1,720 |
Prepaid expenses | 2,622 | 167 |
Total current assets | 132,365 | 74,945 |
Property and equipment, net | 4,593 | 4,470 |
Total assets | 136,958 | 79,415 |
Current liabilities: | ||
Accounts payable | 1,311 | 537 |
Related party payable | 290 | 145 |
Accrued expenses | 3,649 | 550 |
Deferred revenue | 0 | 2,717 |
Current portion of long-term debt | 0 | 1,359 |
Total current liabilities | 5,250 | 5,308 |
Preferred unit warrant liability | 0 | 320 |
Long-term debt, less current portion | 0 | 2,412 |
Total liabilities | 5,250 | 8,040 |
Commitments and contingencies (Note 10) | ||
Convertible preferred units | 0 | 184,714 |
Stockholders' equity / members' deficit: | ||
Common units | 0 | 664 |
Preferred stock, $0.0001 par value - 20,000 shares authorized ; none issued and outstanding as of September 30, 2021 | 0 | 0 |
Additional Paid in Capital | 54,503 | 0 |
Accumulated deficit | (3,142) | (114,003) |
Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc. / (member's deficit) | 51,366 | (113,339) |
Non-controlling interest | 80,342 | 0 |
Total stockholders' equity / (members' deficit) | 131,708 | (113,339) |
Total liabilities, convertible preferred units and stockholders' equity / (members' deficit) | 136,958 | 79,415 |
Common Class A [Member] | ||
Stockholders' equity / members' deficit: | ||
Common stock, value | 2 | 0 |
Common Class B [Member] | ||
Stockholders' equity / members' deficit: | ||
Common stock, value | 3 | 0 |
Common Class C [Member] | ||
Stockholders' equity / members' deficit: | ||
Common stock, value | $ 0 | $ 0 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) | Sep. 30, 2021$ / sharesshares |
Preferred stock, par value | $ / shares | $ 0.0001 |
Preferred stock authorized | 20,000,000 |
Preferred stock issued | 0 |
Preferred stock outstanding | 0 |
Common Class A [Member] | |
Common stock par value | $ / shares | $ 0.0001 |
Common stock shares authorized | 800,000,000 |
Common stock shares issued | 19,712,000 |
Common stock shares outstanding | 19,712,000 |
Common Class B [Member] | |
Common stock par value | $ / shares | $ 0.0001 |
Common stock shares authorized | 40,000,000 |
Common stock shares issued | 29,290,000 |
Common stock shares outstanding | 29,290,000 |
Common Class C [Member] | |
Common stock par value | $ / shares | $ 0.0001 |
Common stock shares authorized | 20,000,000 |
Common stock shares issued | 0 |
Common stock shares outstanding | 0 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Contract revenue | $ 0 | $ 108 | $ 2,717 | $ 252 |
Operating expenses | ||||
Research and development | 11,959 | 2,090 | 19,065 | 8,708 |
General and administrative | 15,822 | 845 | 21,889 | 3,144 |
Total operating expenses | 27,781 | 2,935 | 40,954 | 11,852 |
Loss from operations | (27,781) | (2,827) | (38,237) | (11,600) |
Other income (expense), net | ||||
Interest income | 13 | 13 | 73 | 87 |
Loss on extinguishment of debt | (700) | 0 | (700) | 0 |
Interest expense and other, net | (110) | (64) | (467) | (66) |
Change in estimated fair value of preferred unit warrant | (85) | 0 | (371) | 655 |
Loss before income taxes | (28,663) | (2,878) | (39,702) | (10,924) |
Income tax expense | (37) | (5) | (81) | (23) |
Net loss and comprehensive loss | (28,700) | (2,883) | (39,783) | (10,947) |
Net loss attributable to non-controlling interest | (25,558) | (2,883) | (36,641) | $ (10,947) |
Net loss attributable to Rani Therapeutics Holdings, Inc. | $ (3,142) | $ (2,883) | $ (3,142) | |
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc., basic and diluted | $ (0.16) | $ (0.16) | ||
Weighted-average Class A common shares outstanding-basic and diluted | 19,437 | 19,437 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Stockholders' Equity/Convertible Preferred Units and Member's Deficit (Unaudited) - USD ($) $ in Thousands | Total | Previously Reported [Member] | IPO to Subsequent Period [Member] | Secondary Sales TransactionsPreviously Reported [Member] | IPO [Member] | Common Class A [Member] | Common Class A [Member]IPO to Subsequent Period [Member] | Common Class A [Member]IPO [Member] | Common Class B [Member] | Common Class B [Member]IPO to Subsequent Period [Member] | Common Class B [Member]IPO [Member] | Convertible Preferred [Member] | Convertible Preferred [Member]Previously Reported [Member] | Convertible Preferred [Member]IPO [Member] | Members' Deficit [Member]Previously Reported [Member] | Members' Deficit [Member]Secondary Sales TransactionsPreviously Reported [Member] | Members' Deficit [Member]IPO [Member] | Common [Member] | Additional Paid in Capital [Member]IPO to Subsequent Period [Member] | Additional Paid in Capital [Member]IPO [Member] | Additional Paid in Capital [Member]IPO [Member]Rani LLC | Noncontrolling Interest [Member]IPO to Subsequent Period [Member] | Noncontrolling Interest [Member]IPO [Member] | Noncontrolling Interest [Member]IPO [Member]Rani LLC | Accumulated Deficit [Member] | Accumulated Deficit [Member]IPO to Subsequent Period [Member] |
Temporary Equity, Beginning Balance at Dec. 31, 2019 | $ 115,505 | |||||||||||||||||||||||||
Temporary Equity, Beginning Balance (in units) at Dec. 31, 2019 | 17,085,000 | |||||||||||||||||||||||||
Beginning Balance at Dec. 31, 2019 | $ (96,636) | $ 664 | $ (97,300) | |||||||||||||||||||||||
Beginning Balance (in units) at Dec. 31, 2019 | 46,890,000 | |||||||||||||||||||||||||
Net loss | (5,350) | (5,350) | ||||||||||||||||||||||||
Temporary Equity, Ending Balance at Mar. 31, 2020 | $ 115,505 | |||||||||||||||||||||||||
Temporary Equity, Ending Balance (in units) at Mar. 31, 2020 | 17,085,000 | |||||||||||||||||||||||||
Ending Balance at Mar. 31, 2020 | (101,986) | $ 664 | (102,650) | |||||||||||||||||||||||
Ending Balance (in units) at Mar. 31, 2020 | 46,890,000 | |||||||||||||||||||||||||
Temporary Equity, Beginning Balance at Dec. 31, 2019 | $ 115,505 | |||||||||||||||||||||||||
Temporary Equity, Beginning Balance (in units) at Dec. 31, 2019 | 17,085,000 | |||||||||||||||||||||||||
Beginning Balance at Dec. 31, 2019 | (96,636) | $ 664 | (97,300) | |||||||||||||||||||||||
Beginning Balance (in units) at Dec. 31, 2019 | 46,890,000 | |||||||||||||||||||||||||
Settlement of preferred unit warrant liability | ||||||||||||||||||||||||||
Temporary Equity, Ending Balance at Sep. 30, 2020 | $ 115,505 | |||||||||||||||||||||||||
Temporary Equity, Ending Balance (in units) at Sep. 30, 2020 | 17,085,000 | |||||||||||||||||||||||||
Ending Balance at Sep. 30, 2020 | (107,583) | $ 664 | (108,247) | |||||||||||||||||||||||
Ending Balance (in units) at Sep. 30, 2020 | 46,890,000 | |||||||||||||||||||||||||
Temporary Equity, Beginning Balance at Mar. 31, 2020 | $ 115,505 | |||||||||||||||||||||||||
Temporary Equity, Beginning Balance (in units) at Mar. 31, 2020 | 17,085,000 | |||||||||||||||||||||||||
Beginning Balance at Mar. 31, 2020 | (101,986) | $ 664 | (102,650) | |||||||||||||||||||||||
Beginning Balance (in units) at Mar. 31, 2020 | 46,890,000 | |||||||||||||||||||||||||
Net loss | (2,714) | (2,714) | ||||||||||||||||||||||||
Temporary Equity, Ending Balance at Jun. 30, 2020 | $ 115,505 | |||||||||||||||||||||||||
Temporary Equity, Ending Balance (in units) at Jun. 30, 2020 | 17,085,000 | |||||||||||||||||||||||||
Ending Balance at Jun. 30, 2020 | (104,700) | $ 664 | (105,364) | |||||||||||||||||||||||
Ending Balance (in units) at Jun. 30, 2020 | 46,890,000 | |||||||||||||||||||||||||
Net loss | (2,883) | (2,883) | ||||||||||||||||||||||||
Temporary Equity, Ending Balance at Sep. 30, 2020 | $ 115,505 | |||||||||||||||||||||||||
Temporary Equity, Ending Balance (in units) at Sep. 30, 2020 | 17,085,000 | |||||||||||||||||||||||||
Ending Balance at Sep. 30, 2020 | (107,583) | $ 664 | (108,247) | |||||||||||||||||||||||
Ending Balance (in units) at Sep. 30, 2020 | 46,890,000 | |||||||||||||||||||||||||
Temporary Equity, Beginning Balance at Dec. 31, 2020 | 184,714 | $ 184,714 | ||||||||||||||||||||||||
Beginning Balance at Dec. 31, 2020 | $ (113,339) | $ (113,339) | ||||||||||||||||||||||||
Issuance of Series E preferred units | 6,320 | |||||||||||||||||||||||||
Exercise of warrant for common units | 13 | 13 | ||||||||||||||||||||||||
Equity-based compensation | $ 453 | $ 453 | ||||||||||||||||||||||||
Net loss | (5,598) | (5,598) | ||||||||||||||||||||||||
Temporary Equity, Ending Balance at Mar. 31, 2021 | 191,034 | |||||||||||||||||||||||||
Ending Balance at Mar. 31, 2021 | (118,471) | (118,471) | ||||||||||||||||||||||||
Temporary Equity, Beginning Balance at Dec. 31, 2020 | 184,714 | 184,714 | ||||||||||||||||||||||||
Beginning Balance at Dec. 31, 2020 | (113,339) | (113,339) | ||||||||||||||||||||||||
Settlement of preferred unit warrant liability | 691 | |||||||||||||||||||||||||
Equity-based compensation | $ 1,010 | |||||||||||||||||||||||||
Net loss | (3,142) | |||||||||||||||||||||||||
Temporary Equity, Ending Balance at Sep. 30, 2021 | 0 | |||||||||||||||||||||||||
Ending Balance at Sep. 30, 2021 | 131,708 | $ 131,708 | $ 2 | $ 3 | $ 54,503 | 80,342 | $ (3,142) | |||||||||||||||||||
Ending Balance (shares) at Sep. 30, 2021 | 19,712,000 | 19,712,000 | 29,290,000 | 29,290,000 | ||||||||||||||||||||||
Temporary Equity, Beginning Balance at Mar. 31, 2021 | 191,034 | |||||||||||||||||||||||||
Beginning Balance at Mar. 31, 2021 | (118,471) | (118,471) | ||||||||||||||||||||||||
Equity-based compensation | 282 | 282 | ||||||||||||||||||||||||
Net loss | (5,485) | (5,485) | ||||||||||||||||||||||||
Temporary Equity, Ending Balance at Jun. 30, 2021 | 191,034 | |||||||||||||||||||||||||
Ending Balance at Jun. 30, 2021 | (123,674) | (123,674) | ||||||||||||||||||||||||
Effects of Organizational Transactions | $ 191,725 | $ 1 | $ 3 | $ (191,725) | $ 127,263 | $ 18,106 | $ 46,352 | |||||||||||||||||||
Effects of Organizational Transactions Shares | 12,048,000 | 29,290,000 | ||||||||||||||||||||||||
Issuance of Class A common stock in connection with the IPO, net of issuance costs $10,686 | 73,648 | $ 1 | $ 73,647 | |||||||||||||||||||||||
Issuance of Class A common stock in connection with the IPO, net of issuance costs $10,686, shares | 7,667,000 | |||||||||||||||||||||||||
Exercise of warrant for common units | 13 | 13 | ||||||||||||||||||||||||
Settlement of preferred unit warrant liability | $ 691 | |||||||||||||||||||||||||
Non-controlling interest adjustment for purchase of newly issued Class A units of Rani LLC with proceeds from the IPO | $ (37,895) | $ 37,895 | ||||||||||||||||||||||||
Equity-based compensation | 17,042 | 1,656 | 17,042 | 646 | ||||||||||||||||||||||
Forfeiture of restricted stock awards | 2 | 1 | 1 | |||||||||||||||||||||||
Forfeiture of restricted stock awards, shares | 3,000 | |||||||||||||||||||||||||
Net loss | (3,142) | $ (20,644) | (7,674) | $ (382) | $ (20,644) | (4,681) | $ (233) | $ (149) | (2,993) | |||||||||||||||||
Temporary Equity, Ending Balance at Sep. 30, 2021 | 0 | |||||||||||||||||||||||||
Ending Balance at Sep. 30, 2021 | $ 131,708 | $ 131,708 | $ 2 | $ 3 | $ 54,503 | $ 80,342 | $ (3,142) | |||||||||||||||||||
Ending Balance (shares) at Sep. 30, 2021 | 19,712,000 | 19,712,000 | 29,290,000 | 29,290,000 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Stockholders' Equity/Convertible Preferred Units and Member's Deficit (Parenthetical) $ in Thousands | 3 Months Ended |
Sep. 30, 2021USD ($) | |
IPO [Member] | |
Stock issuance costs | $ 10,686 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Cash flows from operating activities | ||
Net loss | $ (39,783) | $ (10,947) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 384 | 447 |
Equity-based compensation expense | 19,431 | 0 |
Change in fair value of preferred unit warrant liability | 371 | (655) |
Loss on extinguishment of debt | 700 | 0 |
Other | 108 | 67 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other assets | (2,455) | (35) |
Related party receivable | 0 | 51 |
Accounts payable | 674 | 1,924 |
Accrued expenses | 2,346 | (259) |
Related party payable | 145 | (1,601) |
Deferred revenue | (2,717) | 2,748 |
Net cash used in operating activities | (20,796) | (8,260) |
Cash flows from investing activities | ||
Purchases of property and equipment | (235) | (944) |
Net cash used in investing activities | (235) | (944) |
Cash flows from financing activities | ||
Proceeds from issuance of preferred units, net of issuance costs | 6,320 | 0 |
Proceeds from exercise of warrants for common units | 26 | 0 |
Proceeds from the Paycheck Protection Program Loan | 0 | 1,254 |
Repayment of the Paycheck Protection Program Loan | (1,254) | 0 |
Proceeds from issuance of convertible note, net of issuance costs | 0 | 2,781 |
Repayment of the convertible debt | (3,314) | 0 |
Principal and interest repayments from related party for note receivable | 1,720 | 0 |
Net cash provided by financing activities | 77,716 | 4,035 |
Net increase (decrease) in cash and cash equivalents | 56,685 | (5,169) |
Cash and cash equivalents, beginning of year | 73,058 | 16,536 |
Cash and cash equivalents, end of year | 129,743 | 11,367 |
Supplemental disclosures of cash flow information | ||
Cash paid for interest | 285 | 0 |
Supplemental disclosures of non-cash investing and financing activities | ||
Property and equipment purchases included in accounts payable and accrued expenses | 284 | 402 |
IPO issuance costs included in accrued expenses | 570 | 0 |
Settlement of preferred unit warrant liability | 691 | |
Exchange of Class A Units of Rani LLC from the Former LLC Owners | 132,527 | |
Common Class A [Member] | ||
Cash flows from financing activities | ||
Proceeds from issuance of Class A common stock sold in the IPO, net of issuance costs | $ 74,218 | $ 0 |
Organization and Nature of Busi
Organization and Nature of Business | 9 Months Ended |
Sep. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Nature of Business | 1. Organization and Nature of Business Description of Business Rani Therapeutics Holdings, Inc. (the "Company") was formed as a Delaware corporation in April 2021 for the purpose of facilitating an initial public offering ("IPO") of its Class A common stock, facilitate certain organizational transactions and to operate the business of Rani Therapeutics, LLC (“Rani LLC”) and its consolidated subsidiary. The Company is a clinical stage biotherapeutics company focusing on advancing technologies to enable the development of orally administered biologics. The Company has developed the RaniPill capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous or intravenous injection of biologics with oral dosing. The Company is headquartered in San Jose, California and operates in one segment. Up to December 31, 2019, Rani LLC maintained no employees of its own and contracted InCube Labs, LLC (“ICL”), the majority common unit holder of Rani LLC and a related party, to provide research, development and administrative services. ICL and Rani LLC have common management and interest holders and, in the course of performing under the terms of the service agreements, ICL employees acted on behalf of Rani LLC. Effective January 1, 2020, the ICL personnel that were substantially dedicated to providing services to Rani LLC were hired by Rani Management Services, Inc. ("RMS") as full-time employees (Note 6). Initial Public Offering and Organizational Transactions In August 2021, the Company closed its initial public offering (“the Offering” or “IPO”) and sold 7,666,667 shares of its Class A common stock, including shares issued pursuant to the exercise in full of the underwriters’ option, for cash consideration of $ 11.00 per share and received approximately $ 73.6 million in net proceeds, after deducting underwriting discounts, offering costs and commissions. The Company used the proceeds from the IPO to purchase 7,666,667 newly issued economic nonvoting Class A units (“Class A Units”) of Rani LLC. In connection with the IPO, the Company was party to the following organizational transactions (the “Organizational Transactions”): Amended and restated Rani LLC’s operating agreement (the “Rani LLC Agreement”) to appoint the Company as the sole managing member of Rani LLC and effectuated an exchange of all outstanding (i) convertible preferred units, automatic or net exercised warrants to purchase preferred units and common units, and common units of Rani LLC, into Class A Units and an equal number of voting noneconomic Class B units (“Class B Units”) and (ii) all Profits Interests into Class A Units. In connection with the closing of the IPO, each LLC interest was exchanged 1 for 0.5282 as determined and predicated on the initial public offering price of the Company’s Class A common stock. Amended and restated the Company’s certificate of incorporation in July 2021, to provide for the issuance of (i) Class A common stock, each share of which entitles its holders to one vote per share , (ii) Class B common stock, each share of which entitles its holders to 10 votes per share on all matters presented to the Company's stockholders , (iii) Class C common stock, which has no voting rights, except as otherwise required by law and (iv) preferred stock; Exchanged 12,047,925 shares of Class A common stock for existing Class A Units of Rani LLC held by certain individuals and entities (the “Former LLC Owners”) on a one-for-one basis; Issued 29,290,391 shares of Class B common stock to the certain individuals and entities that continued to hold Class A Units in Rani LLC after the IPO (the “Continuing LLC Owners”) in return for an equal amount of Rani LLC Class B Units; Entered into a registration rights agreement with certain of the Continuing LLC Owners. The Continuing LLC Owners are entitled to exchange, subject to the terms of the Rani LLC Agreement, the Class A Units they hold in Rani LLC, together with the shares they hold of the Company Class B common stock (together referred to as a "Paired Interest"), in return for shares of the Company’s Class A common stock on a one-for-one basis provided that, at the Company’s election, the Company may effect a direct exchange of such Class A common stock or make a cash payment equal to a volume weighted average market price of one share of Class A common stock for each Paired Interest redeemed. Any shares of Class B common stock will be cancelled on a one-for-one basis if the Company, at the election of the Continuing LLC Owners, redeems or exchanges such Paired Interest pursuant to the terms of the Rani LLC Agreement. These exchanges and redemptions may result in increases in the tax basis of the assets of Rani LLC that otherwise would not have been available. Increases in tax basis resulting from such exchanges may reduce the amount of tax that the Company would otherwise be required to pay in the future. This tax basis may also decrease the gains (or increase the losses) on future dispositions of certain assets to the extent tax basis is allocated to those assets. Certain individuals who continue to own interests in Rani LLC but do not hold shares of the Company’s Class B common stock can exchange their Class A Units for 1,545,811 shares of the Company’s Class A common stock. Liquidity The Company has incurred recurring losses since its inception, including net losses of $ 39.8 million for the nine months ended September 30, 2021, of which $3.1 million was attributable to Rani Therapeutics Holdings, Inc. for the nine months ended September 30, 2021. As of September 30, 2021, the Company had an accumulated deficit of $3.1 million and for the nine months ended September 30, 2021 had negative cash flows from operations of $ 20.8 million. The Company expects to continue to generate operating losses and negative operating cash flows for the foreseeable future as it continues to develop the RaniPill capsule. The Company expects that its cash and cash equivalents of $ 129.7 million as of September 30, 2021 will be sufficient to fund its operations through at least one year from the date the condensed consolidated financial statements are issued. The Company expects to finance its future operations with its existing cash and through strategic financing opportunities that could include, but are not limited to, future offerings of its equity, collaboration or licensing agreements, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders and holders of interests in the Company. The Company will not generate any revenue from product sales unless, and until, it successfully completes clinical development and obtains regulatory approval for the RaniPill capsule. If the Company obtains regulatory approval for the RaniPill capsule, it expects to incur significant expenses related to developing its internal commercialization capability to support manufacturing, product sales, marketing, and distribution. The Company’s ability to raise additional capital through either the issuance of equity or debt, is dependent on a number of factors including, but not limited to, the demand for the Company, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company operates and controls all of the business and affairs of Rani LLC, and through Rani LLC and its subsidiary, conducts its business. Because the Company manages and operates the business and controls the strategic decisions and day-to-day operations of Rani LLC and also has a substantial financial interest in Rani LLC, the Company consolidates the financial results of Rani LLC, and a portion of its net loss is allocated to the non-controlling interests in Rani LLC held by the Continuing LLC Owners. All intercompany accounts and transactions have been eliminated in consolidation. The Organizational Transactions were considered transactions between entities under common control. As a result, the condensed consolidated financial statements for periods prior to the IPO and the Organizational Transactions have been adjusted to combine the previously separate entities for presentation purposes. Unaudited Interim Financial Information The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of our operations and cash flows for interim periods in accordance with U.S. GAAP. All such adjustments are of a normal, recurring nature. Operating results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any future period. The consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these interim condensed financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company's Registration Statement on Form S-1 (No. 333-257809) filed with the SEC. Variable Interest Entities The Company consolidates all entities that it controls through a majority voting interest or as the primary beneficiary of a variable interest entity (“VIE”). In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company’s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation event. Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Estimates include, but are not limited to, revenue recognition, recovery of long-lived assets, equity-based compensation, accrued research and development costs and the fair value of Profits Interests and preferred unit warrants. Actual results may differ materially and adversely from these estimates. Revenue Recognition The Company enters into evaluation arrangements with certain pharmaceutical partners, under which the Company performs evaluation services of the partner’s drug molecules using the RaniPill capsule. Revenue is recognized when control of promised goods or services is transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Revenue for an individual contract is recognized at the related transaction price, which is the amount the Company expects to be entitled to in exchange for transferring these services. The terms of the evaluation services agreements usually include payments for evaluation services and evaluation milestones based on a decision to extend the agreement. The transaction price of the evaluation services contracts may include variable consideration. Application of the constraint for variable consideration requires judgment. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. For arrangements where the anticipated period between timing of transfer of services and the timing of payment is one year or less, the Company has elected to not assess whether a significant financing component exists. The Company recognizes evaluation services revenue over the period in which evaluation services are provided. Specifically, the Company recognizes revenue using an output method to measure progress, using samples processed relative to total expected samples to be processed as its measure of progress. For services under these arrangements, costs incurred are included in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss. Customer options, such as options granted to allow a customer to acquire later stage evaluation services, are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes. Revenue is recognized for each distinct performance obligation as control is transferred to the customer. The Company recognizes revenue from its evaluation services over time as services are delivered, using a cost-based input method of revenue recognition over the contract term. The cost-based input measured is based on an estimate of total costs to be incurred to deliver the services over the contract period compared to costs incurred to date for each contract. The Company’s evaluation of estimated costs to perform the services typically includes estimates for effort related to contracted research, formulation, and animal testing. These estimates are based on the Company’s reasonable assumptions and its historical experience. Actual results may differ materially and adversely from these estimates. Incremental costs of obtaining contracts are expensed when incurred when the amortization period of the assets that otherwise would have been recognized is one year or less. To date none of these costs have been material. The costs to fulfill the contracts are determined to be immaterial and are recognized as an expense when incurred. Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract receivable when it has an unconditional right to consideration. No contract assets balance was recorded as of September 30, 2021 or December 31, 2020. Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of performance or where the Company has unsatisfied performance obligations. As of December 31, 2020 the Company had deferred revenue of $ 2.7 million. There was no deferred revenue as of September 30, 2021 . Concentrations of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions in excess of federally insured limits. The Company also holds money market funds that are not federally insured. However, management believes the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which these deposits are held and of the money market funds and other entities in which these investments are made. In December 2019, a novel strain of coronavirus, which causes the disease known as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 coronavirus has spread globally. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The COVID-19 pandemic has impacted and may continue to impact the Company’s third-party manufacturers and suppliers, which could disrupt its supply chain or the availability or cost of materials. The effects of the public health directives and the Company’s work-from-home policies may negatively impact productivity, disrupt its business, and delay clinical programs and timelines and future clinical trials, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct business in the ordinary course. These and similar, and perhaps more severe, disruptions in the Company’s operations could negatively impact business, results of operations and financial condition, including its ability to obtain financing. To date, the Company has not incurred impairment losses in the carrying values of its assets as a result of the pandemic and is not aware of any specific related event or circumstances that would require the Company to revise its estimates reflected in these condensed consolidated financial statements. The Company cannot be certain what the overall impact of the COVID-19 pandemic will be on its business and prospects. The extent to which the COVID-19 pandemic will further directly or indirectly impact its business, results of operations, financial condition, and liquidity, including planned and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related effects. In addition, the Company could see some limitations on employee resources that would otherwise be focused on its operation, including but not limited to sickness of employees or their families, the desire of employees to avoid contact with large groups of people, and increased reliance on working from home. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s business, financial condition, results of operations and prospects may be adversely affected. Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying values of the Company’s cash equivalents, prepaid expenses, accounts payable, and accruals approximate their fair value due to their short-term nature. The fair value of the Company’s long-term debt approximated its carrying value based on borrowing rates currently available to the Company for debt with similar terms and maturities (Level 2 inputs). To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized in Level 3 (Note 3). A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument. Research and Development Costs Research and development costs are expensed as incurred. Research and development expenses consist primarily of contract research fees and process development, outsourced labor and related expenses for personnel, facilities cost, fees paid to consultants and advisors, depreciation and supplies used in research and development and costs incurred under our evaluation agreements. Payments made prior to the receipt of goods or services to be used in research and development activities are recorded as prepaid expenses until the related goods or services are received. Until future commercialization is considered probable and the future economic benefit is expected to be realized the Company does not capitalize pre-launch inventory costs. Costs of property and equipment related to scaling-up of the manufacturing capacity for clinical trials and to support commercialization are capitalized as property and equipment unless the related asset does not have an alternative future use. Clinical and preclinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services. Equity-Based Compensation Stock-Based Compensation In July 2021, the Company adopted and its stockholders approved, the Rani Therapeutics Holdings, Inc. 2021 Equity Incentive Plan (the “2021 Plan”). The Company has subsequently granted stock options to purchase shares of its Class A common stock as well as restricted stock units (“RSUs”) and restricted stock awards ("RSAs") from the 2021 Plan to both employees and non-employees. The Company measures stock-based compensation at fair value on the grant date of the award. The fair value of employee and nonemployee RSUs is determined based on the number of shares granted and the closing market price of the Company’s Class A common stock on the date of grant. The fair value of employee RSA's is determined based on the estimated fair value of the Company’s Class A common stock on the grant date and is subject to the Company's reacquisition right which is accounted for as a forfeiture provision (Note 9). For awards that vest subject to the satisfaction of service requirements, compensation expense is measured based on the fair value of the award on the date of grant and expense is recognized on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur. Stock-based compensation is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company determines the grant-date fair value of options to purchase common shares using the Black-Scholes option-pricing model which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company’s expected dividend yield . Such assumptions represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. If actual results are not consistent with the Company’s assumptions and judgments used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company’s consolidated results of operations. Unit-Based Compensation Prior to the IPO, Rani LLC had granted equity-based awards to employees, Board Managers and nonemployees, including ICL employees and consultants, in the form of non-vested incentive units (“Profits Interests”) and/or options to purchase common units. All awards of Profits Interests and options to purchase common units were measured based on the estimated fair value of the award on the date of grant. Forfeitures were recognized when they occurred. All of the Profits Interests were subject to service and performance-based conditions and the Company evaluated the probability of achieving each performance-based condition at each reporting date and recognized equity-based compensation expense for employee and consultant awards and distributions of equity for ICL employee awards in the condensed consolidated financial statements when it was deemed probable that the performance-based condition would be met using the accelerated attribution method over the requisite service period. The options to purchase common units were subject to service conditions and generally vested over three or four years. The Company utilized estimates and assumptions in determining the fair value of its Profits Interests and options to purchase common units on the date of grant. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation , to estimate the fair value of its preferred units, common units and Profits Interests. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include several objective and subjective factors, including probability weighting of events, volatility, time to an exit event, a risk-free interest rate, the prices at which the Company sold preferred units, the superior rights, and preferences of the preferred units senior to the Company’s common units at the time, and a discount for the lack of marketability. Changes to the key assumptions used in the valuations could result in different fair values at each valuation date. Tax Receivable Agreement In August 2021, in connection with the IPO and Organizational Transactions, the Company entered into a tax receivable agreement ("TRA") with certain of the Continuing LLC Owners. The TRA provides that the Company pay to such Continuing LLC Owners, 85 % of the amount of tax benefits, if any, it is deemed to realize (calculated using certain assumptions) as a result of (i) increases in the tax basis of assets of Rani LLC resulting from (a) any future redemptions or exchanges of Paired Interests and (b) payments under the TRA and (ii) certain other benefits arising from payments under the TRA (collectively the “Tax Attributes”). A liability for the payable to parties subject to the TRA, and a reduction to stockholders’ equity, is accrued when (i) an exchange of a Paired Interest has occurred and (ii) when it is deemed probable that the Tax Attributes associated with the exchange will be used to reduce the Company’s taxable income based on the contractual percentage of the benefit of Tax Attributes that the Company expects to receive over a period of time. No exchanges of Paired Interests had occurred through September 30, 2021 and therefore no liability had been accrued for the TRA. Comprehensive Loss Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions and other events and/or circumstances from non-owner sources. The Company did not have any other comprehensive loss for any of the periods presented, and therefore comprehensive loss was the same as the Company’s net loss. Net Loss Per Class A Common Share Attributable to Rani Therapeutics Holdings, Inc. Basic net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. is computed by dividing net loss attributable to the Company by the weighted average number of Class A Common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per Class A Common share is computed giving effect to all potentially dilutive shares. Diluted net loss per Class A Common share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. Net loss per share is not presented for the three and nine months ended September 30, 2020 as the Company did not have any economic interests prior to the date of the IPO and Organizational Transactions through which it was given ownership in Rani LLC. Losses prior to the IPO and Organizational Transactions would have been allocated to the original members of Rani LLC. The basic and diluted net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. for the three and nine-months ended September 30, 2021 is applicable only for the period from August 4, 2021 to September 30, 2021, which is the period following the IPO and Organizational Transactions and represents the period that the Company had Class A common shares outstanding. Non-Controlling Interest Non-controlling interest ("NCI") represents the portion of income or loss, net assets and comprehensive loss of our consolidated subsidiary that is not allocable to the Company based on the Company's percentage of ownership of Rani LLC. In August 2021, based on the Organizational Transactions, the Company became the sole managing member of Rani LLC. As of September 30, 2021, the Company held approximately 39 % of the Class A Units of Rani LLC, and approximately 61 % of the outstanding Class A Units of Rani LLC are held by the Continuing LLC Owners. Therefore, the Company reports NCI based on the Class A Units of Rani LLC held by the Continuing LLC Owners on its condensed consolidated balance sheet as of September 30, 2021. Income or loss attributed to the NCI in Rani LLC is based on the Class A Units outstanding during the period for which the income or loss is generated and is presented on the condensed consolidated statements of operations and comprehensive income or loss. Future exchanges of Paired Interests will result in a change in ownership and reduce or increase the amount recorded as NCI and increase or decrease additional paid-in-capital when Rani LLC has positive or negative net assets, respectively. From the date of the Organizational Transactions to September 30, 2021, there were no exchanges of Paired Interests. New Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-02, Leases (“Topic 842”), as subsequently amended, to improve financial reporting and disclosures about leasing transactions. Topic 842 requires companies that lease assets to recognize on the condensed consolidated balance sheet the assets and liabilities for the rights and obligations created by those leases, where the lease terms exceed 12 months. The recognition, measurement, and presentation of expense and cash flows arising from a lease by a lessee will depend primarily on its classification as a finance or operating lease; both types of leases will be recognized on the condensed consolidated balance sheet. Topic 842 also requires disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. On June 3, 2020, the FASB amended the effective dates of Topic 842 to give immediate relief from business disruptions caused by the COVID-19 pandemic and provided a one-year deferral of the effective date for nonpublic companies. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, and assuming the Company continues to be considered an emerging growth company, Topic 842 will be effective for the Company on January 1, 2022. The Company has not yet determined the effects of Topic 842 on its condensed consolidated financial statements but does expect the adoption of Topic 842 will have a material impact on the Company’s consolidated financial statements and related notes to the recognition of right of use (“ROU”) assets and lease liabilities on the Company’s consolidated balance sheets, but it will not have a material impact on the Company’s consolidated statement of income. The adoption of Topic 842 will also result in enhanced disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (“ASU 2016-13”) to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, and assuming the Company continues to be considered an emerging growth company, ASU 2016-13 will be effective for the Company on January 1, 2023. The Company has not yet determined the potential effects of ASU 2016-13 on its condensed consolidated financial statements and disclosures. |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Sep. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 3. Fair Value Measurements The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of inputs used in such measurements (in thousands): As of September 30, 2021 Level 1 Level 2 Level 3 Assets: Money market funds $ 126,363 $ — $ — Total assets $ 126,363 $ — $ — As of December 31, 2020 Level 1 Level 2 Level 3 Assets: Money market funds $ 71,666 $ — $ — Total assets $ 71,666 $ — $ — Liabilities: Preferred unit warrant liability $ — $ — $ 320 Total liabilities $ — $ — $ 320 There were no financial liabilities measured at fair value on a recurring basis as of September 30, 2021. The Company estimates the fair value of its money market funds by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. There were no transfers between Level 1, Level 2 and Level 3 of the fair value hierarchy for any of the periods presented. The Company held a Level 3 liability associated with preferred unit warrants that were issued in conjunction with a loan and security Agreement (Note 11). These preferred unit warrants were settled with Class A common stock as part of the IPO and Organizational Transactions (Note 7). The following tables set forth a summary of the changes in the fair value of the Company’s liability measured using Level 3 inputs (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Balance at beginning of period $ 606 $ — $ 320 $ 655 Change in estimated fair value of Series B warrants — — — 16 Change in estimated fair value of Series E warrants 85 — 371 — Expiration of Series B warrants — — — ( 671 ) Settlement of Series E warrants ( 691 ) ( 691 ) Balance at end of period $ — $ — $ — $ — |
Accrued Expenses
Accrued Expenses | 9 Months Ended |
Sep. 30, 2021 | |
Accrued Liabilities [Abstract] | |
Accrued Expenses | 4. Accrued Expenses Accrued expenses consist of the following (in thousands): September 30, December 31, 2021 2020 Accrued professional fees $ 379 $ — Payroll and related 1,951 136 IPO issuance costs 570 — Other 749 414 Total accrued expenses $ 3,649 $ 550 |
Evaluation Agreements
Evaluation Agreements | 9 Months Ended |
Sep. 30, 2021 | |
Evaluation Agreements [Abstract] | |
Evaluation Agreements | 5. Evaluation Agreements Takeda Takeda Pharmaceutical Company, Limited ("Takeda") was collaborating with the Company to conduct research on the use of the RaniPill capsule for the oral delivery of factor VIII (“FVIII”) therapy for patients with hemophilia A. The agreement granted Takeda a right of first negotiation to a worldwide, exclusive license under the Company’s intellectual property related to a FVIII-RaniPill therapeutic. Takeda paid the Company up-front payments of $ 5.9 million upon execution of and subsequent modifications to the agreement. Upon the initial evaluation services being completed, Takeda had an option to pay the Company $ 3.0 million to perform later stage evaluation services. Takeda also had the ability to terminate the agreement at any time by providing 30 days written notice after the effective date of the agreement. Unless terminated early, the agreement term ended upon the expiration of the right of first negotiation period which is 120 days after the completion of the evaluation services. The Takeda agreement could be terminated for cause by either party based on uncured material breach by the other party or bankruptcy of the other party. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses would terminate. The Company identified one material promise under the Takeda agreement, the obligation to perform services to evaluate if Takeda’s FVIII therapy can be orally delivered using the RaniPill capsule (“Research and Development Services”), which was concluded be a single performance obligation. For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in November 2017 and ends upon completion of the Research and Development Services. The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. The Company also analyzed the impact of Takeda terminating the agreement prior to the completion of the performance obligation and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to Takeda for doing so. The Company has determined that the cost-based input method most faithfully depicts the transfer of its performance obligation to Takeda. Accordingly, the Company recognized its contract revenue based on actual costs incurred as a percentage of total estimated costs the Company expected to incur to deliver its performance obligation. These actual costs consisted of internal labor efforts, in vivo testing services and materials costs related to the Takeda agreement, as the costs incurred over time reflect the transfer of its performance obligations to Takeda. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligation was recorded in the period in which changes were identified and amounts were reasonably estimable. In May 2021, the Company received written notice from Takeda as to their intent to terminate the contract for convenience. Due to the delivery of the termination notice, the Company determined that there were no further enforceable rights and obligations under the agreement beyond May 2021 and the remaining $ 2.0 million of deferred revenue was recognized during the nine months ended September 30, 2021 . For the three months ended September 30, 2021 , no contract revenue related to the Takeda agreement was recognized. For the three months ended September 30, 2020 , the Company recognized contract revenue related to the Takeda agreement of $ 0.1 million. For the nine months ended September 30, 2021 and 2020 , the Company recognized contract revenue related to the Takeda agreement of $ 2.7 million and $ 0.3 million, respectively. As of December 31, 2020 , deferred revenue related to the remaining identified performance obligation for the Takeda agreement of $ 2.7 million was recorded on the condensed consolidated balance sheets. There was no deferred revenue as of September 30, 2021. Changes in the deferred revenue balance are as follows (in thousands): September 30, December 31, 2021 2020 Balance at beginning of period $ 2,717 $ 179 Additions — 3,000 Deductions ( 2,717 ) ( 462 ) Balance at end of period $ — $ 2,717 There were no receivables or net contract assets recorded as of September 30, 2021 or December 31, 2020 associated with the Takeda agreement. The Company expensed all incremental costs of obtaining the Takeda agreements, as such amounts were insignificant. |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Sep. 30, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 6. Related Party Transactions ICL is wholly-owned by the Company’s founder and Executive Chairman and his family. The Company’s Chief Scientific Officer is the brother of the founder and Executive Chairman and uncle of the Company’s Chief Executive Officer. The founder and Executive Chairman is also the father of the Company’s Chief Executive Officer. Services agreements In January 2019, the Company, through its subsidiary, entered into a one year service agreement with ICL. This agreement was amended in January 2020 to extend the period for an additional year and expired in December 2020. The Company is presently operating under a service agreement with ICL executed in June 2021, retroactive to January 1, 2021. The Company or ICL may terminate services under the service agreement upon 60 days' notice to the other party, except for occupancy which requires six months' notice. The service agreement specifies the scope of services to be provided by ICL as well as the methods for determining the costs of services for the year ended December 31, 2021. Costs are billed on a monthly basis and based upon the hours incurred by ICL employees working on behalf of the Company as well as allocations of expenses based upon the Company’s utilization of ICL’s facilities and equipment. In June 2021, RMS entered into the RMS-ICL Service Agreement with ICL effective January 1, 2021 (the "RMS-ICL Service Agreement"), pursuant to which ICL agreed to rent a specified portion of its facility to RMS. Additionally, RMS and ICL agreed to provide personnel services to the other upon requests based on rates specified in the agreement. The RMS-ICL Service Agreement has a 12-month term and will automatically renew for successive 12-month periods unless terminated. For the nine months ended September 30, 2020 and 2021, RMS charged ICL $ 0.3 million and $ 0.5 million for services performed, respectively, and such amounts charged were recorded as a reduction to research and development expense in the condensed consolidated statement of operations and comprehensive loss. The table below details the amounts charged by ICL for services and rent, net of the amount that RMS charged ICL, which is included in the condensed consolidated statements of operations and comprehensive loss (in thousa nds): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Research and development $ 222 $ ( 22 ) $ 377 $ 98 General and administrative 149 174 516 625 Total $ 371 $ 152 $ 893 $ 723 The Company’s eligible employees are permitted to participate in ICL’s 401(k) Plan (“401(k) Plan”). Participation in the 401(k) Plan is offered for the benefit of the employees, including the Company’s named executive officers, who satisfy certain eligibility requirements. As of September 30, 2021, all of the Company's facilities are owned by an entity affiliated with the Company’s Executive Chairman. The Company pays for the use of these facilities through the services agreement with ICL. Financing activity From inception to the first half of 2017, the Company advanced funds to ICL, and ICL made payments directly to certain vendors on behalf of Rani, Rani has reimbursed ICL for all such payments at cost on a monthly basis. In June 2017, the Company converted the outstanding net advances of $ 6.6 million to ICL into three notes receivable. The notes provide for interest at 1.97 % compounded annually, loan fees of 2.75 % and are payable upon demand to the Company any time after January 1, 2024. During 2020, the Company received $ 0.2 million in payments for interest and repayment of principal on the remaining notes receivable. As of December 31, 2020, $ 1.7 million of the notes receivable was outstanding. In March 2021, the outstanding balance due, including all accrued interest, was fully repaid by ICL. During 2020, the Company amended certain Series B warrants held by an entity affiliated with ICL. In December 2020, this entity elected to cashless exercise all of their Series B warrants in return for 51,341 Series B units (Note 7). This same entity also acquired 59,312 Series D units for $ 1.0 million in 2017. During 2020 and 2021, South Lake One LLC, a related party of the Company, and its Affiliates purchased 7,880,120 Series E Preferred Units of Rani LLC at $ 7.1471 per unit. As part of the Organizational Transactions the Series E Preferred Units were exchanged for 5,277,729 shares of the Company's Class A common stock. In connection with the IPO and subsequent thereto, South Lake One LLC and its Affiliates purchased an additional 6,458,904 shares of the Company’s Class A common stock for total gross proceeds of $ 71.1 million. Exclusive License, Intellectual Property and Common Unit Purchase Agreement The Company, through Rani LLC, and ICL entered into an exclusive license and an intellectual property agreement and common unit purchase agreement in 2012. Pursuant to the common unit purchase agreement, the Company issued 46.0 million common units to ICL in return for rights to exclusive commercialization, development, use and sale of certain products and services related to the RaniPill capsule technology. ICL also granted the Company a fully-paid, royalty-free, sublicensable, exclusive license under the intellectual property made by ICL during the course of providing services to the Company related to the RaniPill capsule technology. Such rights were not recorded on the Company’s condensed consolidated balance sheet as the transaction was considered a common control transaction. In June 2021, ICL and the Company, through Rani LLC, entered into an Amended and Restated Exclusive License Agreement which replaces the 2012 Exclusive License Agreement, as amended in 2013, and terminates the Intellectual Property Agreement, as amended in June 2013. Under the Amended and Restated License Agreement, the Company will have a fully paid, exclusive license under certain scheduled patents related to optional features of the device and certain other scheduled patents to exploit products covered by those patents in the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine. The Company will cover patent-related expenses and, after a certain period, the Company will have the right to acquire four specified U.S. patent families from ICL by making a one-time payment of $ 0.3 million to ICL for each U.S. patent family that the Company desires to acquire, up to $ 1.0 million in the aggregate. This payment will not become an obligation until the fifth anniversary of the Amended and Restated Exclusive License Agreement. The Amended and Restated Exclusive License Agreement will terminate when there are no remaining valid claims of the patents licensed under the Amended and Restated Exclusive License Agreement. Additionally, the Company may terminate the Amended and Restated Exclusive License Agreement in its entirety or as to any particular licensed patent upon notification to ICL of such intent to terminate. Non-Exclusive License Agreement between Rani and ICL (“Non-Exclusive License Agreement”) In June 2021, the Company, through Rani LLC, entered into the Non-Exclusive License Agreement with ICL a related party, pursuant to which the Company granted ICL a non-exclusive, fully-paid license under specified patents that were assigned from ICL to the Company. Additionally, the Company agreed not to license these patents to a third party in a specific field outside the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine, if ICL can prove that it or its sublicensee has been in active development of a product covered by such patents in that specific field. ICL may grant sublicenses under this license to third parties only with the Company’s prior approval. The Non-Exclusive License Agreement will continue in perpetuity unless earlier terminated. Intellectual Property Agreement with Mir Imran (the “Mir Agreement”) In June 2021, the Company, through Rani LLC, entered into the Mir Agreement, pursuant to which the Company and Mir Imran agreed that the Company would own all intellectual property conceived (a) using any of the Company’s people, equipment, or facilities or (b) that is within the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine. Neither the Company nor Mir Imran may assign the Mir Agreement to any third party without the prior written consent of the other party. The initial term of the Mir Agreement is three years, which can be extended upon mutual consent of the parties. The Mir Agreement may be terminated by either party for any reason within the initial three year term upon providing three months’ notice to the other party. Board Services During the year ended December 31, 2020, the Company made a $ 0.2 million payment to a member of the Board of Managers for legacy board services provided to the Company. Secondary Sales Transactions In February 2021, one of the Company's named executive officer's and then member of the Board of Managers, and a current member of the Board of Managers sold a total of 210,000 common units to a third-party investor at $ 7.1471 per unit. The Company determined that the sales price was above fair value of such units and as a result recorded equity-based compensation expense of $ 0.5 million for which $ 0.2 million was recorded as general and administrative expense and $ 0.3 million was recorded as research and development expense. The $ 0.5 million represents the difference between the sales price and fair value of the common units. Equity-Based Compensation In connection with the IPO and Organizational Transactions, the Company effectuated an exchange of all outstanding Profits Interests into Class A Units including certain Profits Interests related to ICL and its affiliates ("ICL Holders"). Upon the IPO and Organizational Transactions, the performance condition was met for all Profits Interest no longer subject to a service based vesting condition resulting in the recognition of compensation cost associated with these awards (Note 9). ICL Holders of 919,282 Class A Units exchanged 854,807 such units for the Company's Class A common stock, the remaining 64,475 Class A Units of Rani LLC continue to be outstanding and are exchangeable for the Company's Class A common stock at the option of the ICL Holders. The following table summarizes the components of equity-based compensation expense recorded in the condensed consolidated statement of operations and comprehensive loss related to awards granted to employees of ICL and its affiliates by the Company (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Research and development $ 644 — $ 644 — General and administrative 2,947 — 2,947 — Total $ 3,591 — $ 3,591 — Tax Receivable Agreement Certain parties to the TRA, entered into in August 2021 pursuant to the IPO and Organizational Transactions, are related parties of the Company. The TRA provides that the Company pay to such entities and individuals 85% of the amount of tax benefits, if any, it is deemed to realize from exchanges of Paired Interests (Note 2). Registration Rights Agreement In connection with the IPO, the Company entered into a Registration Rights Agreement. ICL is a party to this agreement. The Registration Rights Agreement provides certain registration rights whereby, at any time following the IPO and the expiration of any related lock-up period, ICL Holders with LLC Interests can require the Company to register under the Securities Act of 1933, as amended (the “Securities Act”) shares of Class A common stock issuable to such ICL Holders upon, at the Company’s election, redemption or exchange of their Paired Interests. The Registration Rights Agreement also provides for piggyback registration rights. The Company operates its business through Rani LLC and its subsidiary. In connection with the IPO, the Company and the Continuing LLC Owners, including ICL, entered into the Rani LLC Agreement. The operations of Rani LLC, and the rights and obligations of the holders of LLC Interests, are set forth in the Rani LLC Agreement. As a Continuing LLC Owner, ICL is entitled to exchange, subject to the terms of the Rani LLC Agreement, Paired Interests for Class A common stock of the Company; provided that, at the Company’s election, the Company may effect a direct exchange of such Class A common stock or make a cash payment equal to a volume weighted average market price of one share of Class A common stock for each Paired Interest redeemed. No exchanges with ICL of Paired Interests occurred during the three and nine months ended September 30, 2021. |
Warrants
Warrants | 9 Months Ended |
Sep. 30, 2021 | |
Warrants and Rights Note Disclosure [Abstract] | |
Warrants | 7. Warrants Preferred unit warrants In September 2020, in conjunction with a loan and security Agreement (Note 11), the Company issued warrants to purchase up to 118,929 Series E preferred units. The Series E warrants were exercisable for a period of seven years from the grant date at an exercise price of $ 7.1471 per unit. In the event of a change of control or IPO, the Series E warrants were to automatically be exchanged for the same number of units of the Company’s securities for no consideration had the holder of the warrant elected to exercise the warrant immediately prior to a change in control or IPO. In conjunction with the IPO, all of the Series E warrants were ultimately settled for 62,887 shares of the Company's Class A common stock. At December 31, 2020 there were 118,929 Series E warrants outstanding. There were no Series E warrants outstanding at September 30, 2021. Common unit warrants In 2017, in conjunction with the Series D convertible preferred unit financing, the Company issued 229,315 common unit warrants with an exercise price of $ 2.18 per unit and an exercise period of five years . The Company recorded the issuance-date fair value of the common warrants of $ 0.3 million in equity as the warrant met all criteria for equity classification. In January 2021, 6,000 common unit warrants were exercised at $ 2.18 per unit, and in July 2021 common unit warrants totaling 5,931 were exercised at $ 2.18 per unit. In connection with the IPO and Organizational Transactions, the remaining common warrants were net exercised for 71,867 Class A Units of Rani LLC of which 60,494 were then exchanged into shares of the Company's Class A common stock as part of the Organizational Transactions. At December 31, 2020 , 229,315 common unit warrants were outstanding. There were no common unit warrants outstanding at September 30, 2021. |
Stockholders' Equity_Members' D
Stockholders' Equity/Members' Deficit | 9 Months Ended |
Sep. 30, 2021 | |
Equity [Abstract] | |
Stockholders' / Members' deficit | 8. Stockholders’ Equity / Members’ Deficit Prior to the Organizational Transactions, Rani LLC was authorized to issue 101,000,000 common units, of which 10,850,000 had been reserved for issuance as Profits Interests and 32,620,000 were reserved for six separate classes, the Series A convertible preferred units (the “Series A units”), the Series B convertible preferred units (the “Series B units”), the Series C convertible preferred units (the “Series C units”), the Series C-1 convertible preferred units (the “Series C-1 units”), the Series D convertible preferred units (the “Series D units”), and the Series E convertible preferred units (the “Series E units”), collectively the “Preferred Units”. The members of the Rani LLC who held these common and Preferred Units were not liable, solely by reason of being a member, for the debts, obligations, or liabilities of the Company whether arising in contract or tort; under a judgment, decree, or order of a court; or otherwise. The members were also not obligated to make capital contributions to the Rani LLC and Rani LLC would have dissolved only upon a written consent of a majority of the members. The Company’s Profits Interests were subject to either a combination of service, market, or performance vesting conditions. Vested Profits Interests were treated as common units for purposes of distributions. Amendment and Restatement of Certificate of Incorporation In connection with the Organizational Transactions, the Company’s certificate of incorporation was amended and restated to, among other things, provide for the (i) authorization of 800,000,000 shares of Class A common stock with a par value of $ 0.0001 per share; (ii) authorization of 40,000,000 shares of Class B common stock with a par value of $ 0.0001 per share; (iii) authorization of 20,000,000 shares Class C common stock with a par value of $ 0.0001 per share; and (iv) authorization of 20,000,000 shares of preferred stock with a par value of $ 0.0001 per share. Holders of Class A common stock are entitled to one vote per share; holders of Class B common stock are entitled to ten votes per share; and holders of Class C common stock have no voting rights. Except as otherwise expressly provided in the Amended and Restated Certificate of Incorporation or as required by law, the holders of Class A common stock and Class B common stock (and, on any matter on which the Class C common stock or the holders of preferred stock are entitled to vote with the Class A common stock and the Class B common stock, the Class C common stock and the preferred stock) will vote together as a single class and not as separate series or classes. The Company is required to, at all times, maintain (i) a one-to-one ratio between the number of shares of Class A common stock outstanding and the number of Class A Units owned by Company and (ii) a one-to-one ratio between the number of shares of Class B common stock owned by the Continuing LLC Owners and the number of Class A Units owned by the Continuing LLC Owners. The Company may issue shares of Class B common stock only to the extent necessary to maintain these ratios. Shares of Class B common stock are not transferable except (a) to the Company for no consideration (in which case the shares will be cancelled automatically) or (b) together with an equal number of Class A Units to a transferee in compliance with the LLC Agreement and the provisions set forth in the Company’s amended and restated certificate of incorporation . All Class B common stock that is exchanged as part of a Paired Interest for Class A common stock shall be automatically retired and cancelled and shall no longer be outstanding. In August 2021, the Company received 29,290,391 Class B Units of Rani LLC as consideration for the issuance of Class B common stock on a one -for-one basis. Management of Rani LLC In August 2021, Rani LLC’s members and Board of Managers adopted the amended and restated Rani LLC Agreement to, among other things, appoint the Company as Rani LLC’s sole managing member and provide that, except where the approval of one or more members is specifically required by the express terms of the Rani LLC Agreement, all management powers over the business and affairs of Rani LLC are vested exclusively in the Company as the sole managing member. Initial Public Offering In July 2021, the Company completed an initial public offering of 7,666,667 shares of common stock, inclusive of the 1,000,000 shares of Class A common stock purchased by underwriters pursuant to the underwriters’ option to purchase additional shares at the initial public offering price, less underwriting discounts and commissions. The Company received net proceeds from the IPO of approximately $ 73.6 million after deducting underwriting discounts and commissions, which was used to purchase 7,666,667 newly-issued Class A Units of Rani LLC. Registration Rights Agreement In connection with the IPO, the Company entered into a Registration Rights Agreement with the Continuing LLC Owners, including ICL. The Registration Rights Agreement provides the Continuing LLC Owners certain registration rights whereby, at any time following the IPO and the expiration of any related lock-up period, the Continuing LLC Owners can require the Company to register under the Securities Act shares of Class A common stock issuable to them upon, at the Company’s election, redemption or exchange of their Paired Interests, and the Former LLC Owners can require the Company to register under the Securities Act the shares of Class A common stock issued to them in connection with the Organizational Transactions. The Registration Rights Agreement also provides for piggyback registration rights for the Continuing LLC Owners. |
Equity Based Compensation
Equity Based Compensation | 9 Months Ended |
Sep. 30, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Equity-Based Compensation | 9. Equity-Based Compensation Stock-Based Compensation In July 2021, in connection with the IPO, the Company adopted and its stockholders approved the 2021 Plan. The 2021 Plan provides for the grant of incentive stock options ("ISOs"), non-statutory stock options ("NSOs"), stock appreciation rights, RSAs, RSUs, performance-based awards and other awards for shares of the Company’s Class A common stock. In July 2021, the Company's board of directors adopted and its stockholders approved, the Rani Therapeutics Holdings, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”). As of September 30, 2021, the ESPP was not yet effective. The Company reserved 500,000 shares of Class A Common Stock for issuance under the ESPP and 5,500,000 shares of Class A common stock for future issuance under the 2021 Plan. Stock Options A summary of stock option activity during the periods indicated is as follows: Number of Stock Option Awards Weighted Average Exercise Price Weighted Aggregate Intrinsic Value (in thousands) Balance at December 31, 2020 — — — Granted as replacement awards 1,212,124 $ 9.44 9.72 $ 10,158 Granted 907,400 $ 17.84 9.92 $ 1,244 Balance at September 30, 2021 2,119,524 $ 13.04 9.81 $ 11,402 Exercisable at September 30, 2021 57,806 $ 9.44 9.72 $ 484 Nonvested at September 30, 2021 2,061,718 $ 13.14 9.81 $ 10,918 In connection with the Organizational Transactions, 2,292,309 options for common units of Rani LLC still subject to service vesting conditions were canceled and replaced with 1,212,124 stock options to acquire the Company’s Class A common stock. This was considered to be a modification but did not result in modification accounting as it did not impact the awards’ vesting conditions, classification or fair value. These stock options vest based on the grantees continued services over a three or four year period. As of September 30, 2021 , there was $ 17.8 million of unrecognized equity-based compensation expense related to stock options which is expected to be recognized over a weighted-average period of approximately 3.5 years. Restricted Stock Units A summary of RSU activity during the periods indicated is as follows: Number of Restricted Stock Units Weighted Average Grant-Date Fair Value per Share Balance at December 31, 2020 — — Granted 599,500 $ 19.56 Forfeited ( 2,000 ) $ 19.56 Balance at September 30, 2021 597,500 $ 19.56 As of September 30, 2021 , there was $ 11.4 million of unrecognized equity-based compensation expense related to RSUs which is expected to be recognized over a weighted-average period of approximately 1.9 years. Restricted Stock Awards A summary of RSA activity during the periods indicated is as follows: Number of Restricted Stock Awards Weighted Average Grant-Date Fair Value per Share Balance at December 31, 2020 — — Granted as replacement of Profits Interests 137,691 $ 5.78 Vested ( 15,058 ) $ 5.72 Forfeited ( 2,718 ) $ 6.11 Balance at September 30, 2021 119,915 $ 5.79 In connection with the IPO and Organizational Transactions, 397,500 Profits Interests of Rani LLC were canceled and replaced with 137,691 RSAs of the Company’s Class A common stock. This was considered to be a modification but did not result in modification accounting as it did not impact the awards’ vesting conditions, classification or fair value. The RSAs are subject to both service vesting conditions and the Company's reacquisition right of unvested RSAs from the holder, for no monetary consideration, upon the termination of continuous service by the holder. The RSAs are not deemed to be issued for accounting purposes until they vest and are therefore excluded from shares outstanding for accounting purposes until the repurchase right lapses and the shares are no longer subject to the reacquisition right. As of September 30, 2021, there was $ 0.7 million of unrecognized equity-based compensation expense related to RSAs which is expected to be recognized over a weighted-average period of approximately 3.3 years. Unit-Based Compensation Prior to the IPO, Rani LLC had adopted the 2016 Equity Incentive Plan (the “2016 Plan”) under which the Board of Managers issued options for common units, Profits Interests, and restricted common units to managers, consultants or other individuals who provide service to the Company. The Board of Managers had the authority to determine to whom Profits Interests would be granted, the number of options granted, and the Profits Interests threshold amount, which was the minimum amount determined by the Board of Managers in its reasonable discretion to be necessary to cause such interests to be treated as Profits Interests (“Threshold Amounts”). In 2020, the Board of Managers approved an additional 2,000,000 common units to be reserved under the Plan for issuance as Profit Interests. Effective April, 2021, in anticipation of the IPO the Company ceased granting Profits Interests and began to issue options for common units out of the remaining pool. In July 2021, the 2016 Plan was terminated concurrent with the adoption of the 2021 Plan. Immediately upon receipt of a Profits Interests award, the recipient had no initial capital account balance and the Profits Interests received did not entitle such recipient to any portion of the capital of Rani LLC at the time of such recipient’s admission to Rani LLC as an unitholder member, such that if Rani LLC’s assets were sold at fair market value immediately after the grant to such recipient of Profits Interests and the proceeds distributed in complete liquidation of Rani LLC, the Profits Interests received would entitle such recipient to receive no portion of those proceeds. Additionally, Rani LLC would not make a distribution with respect to any Profits Interests unless Rani LLC had made aggregate distributions to each interest subject to a lower or no Profits Interests Threshold Amount. The common units underlying each Profits Interests award entitled the holder, upon a sale or other specified capital transaction (as set forth in the Operating Agreement), to participate in a portion of the profits and appreciation in the equity value of Rani LLC arising after the date of grant, as determined in reference to the Profits Interests Threshold Amount set forth in each award agreement. Profits Interests A summary of Profits Interests activity during the periods indicated is as follows: Number of Weighted Profits Balance at December 31, 2020 6,926,358 $ 1.63 $ 1.44 - $ 2.29 Granted 1,857,000 $ 2.13 $ 1.99 - $ 2.13 Forfeited ( 235,957 ) $ 2.04 $ 1.45 - $ 2.29 Vested ( 8,149,901 ) $ 1.70 $ 1.44 - $ 2.29 Canceled and replaced with restricted stock awards ( 397,500 ) $ 2.13 $ 1.99 - $ 2.13 Balance at September 30, 2021 — $ — In connection with the IPO and Organizational Transactions, 1,771,767 units of unvested Profits Interests that contained a performance condition were modified to accelerate their vesting in return for exchanging such awards for shares of the Company’s Class A common stock upon an IPO. Concurrent with the IPO, such Profits Interests holders exchanged their then issued 3,201,220 Class A Units of Rani LLC for 1,655,409 shares of the Company’s Class A common stock. This resulted in an improbable to improbable modification and resulted in the remeasurement of the related compensation cost at the fair value of these Profits Interests on the modification date in July 2021. As a result of the modification and based on the performance condition being satisfied with the IPO and Organizational Transactions in July 2021, the Company recognized an incremental equity-based compensation expense of $ 3.0 million for the three and nine months ended September 30, 2021. Profits Interests of 397,500 still subject to service based vesting, but where the performance condition associated with the IPO and Organizational Transactions had been met, were exchanged for 137,691 RSAs with the same remaining service vesting conditions. All Profits Interests no longer subject to a vesting condition and that did not participate in the exchange, were converted into 1,545,811 Class A Units of Rani LLC. Upon the IPO and Organizational Transactions, the performance condition was met for all Profits Interest no longer subject to a service based vesting condition and the Company recorded an additional $ 14.0 million of equity-based compensation expense. Options for Common Units A summary of options for common units activity during the periods indicated is as follows: Number of Unit Option Awards Weighted Average Exercise Price Weighted Aggregate Intrinsic Value (in thousands) Balance at December 31, 2020 — — — Granted 2,292,309 4.99 9.89 Canceled and replaced with stock options ( 2,292,309 ) 4.99 9.89 Balance at September 30, 2021 — — — — Throu gh July 2021, the Company granted options to acquire 2,292,309 common units of Rani LLC to certain executives and members of the Board of Managers. In conjunction with the Organizational Transactions, these unit options were canceled and replaced with stock options of the Company. The following table summarizes the components of equity-based compensation expense resulting from the grant of stock options, RSUs, RSAs, Profits Interests, and options for common units, recorded in the Company’s condensed consolidated statement of operations and comprehensive loss (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 6,635 — $ 6,696 — General and administrative 12,061 — 12,282 — Total equity-based compensation $ 18,696 — $ 18,978 — |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 10. Commitments and Contingencies Leases Rani LLC pays for the use of its office, laboratory and manufacturing facilities in San Jose, California as part of the services agreement with ICL (Note 6), which is accounted for as an operating lease with an implied renewal option into 2025. Rent expense incurred with ICL was $ 0.6 million for each of the nine month periods ended September 30, 2021 and 2020. Legal Proceedings In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is currently involved in several opposition proceedings at the European Patent Office, all of which were asserted against us by Novo Nordisk AS. The ultimate outcome of this matter as a loss is not probable nor is there any amount that is reasonably estimable. However, the outcome of the opposition proceedings could impact the Company’s ability to commercialize its products in Europe. |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 12. Income Taxes The Company is the managing member of Rani LLC and, as a result, consolidates the financial results of Rani LLC and its taxable subsidiary RMS in the unaudited condensed consolidated financial statements. Rani LLC is a pass-through entity for U.S. federal and most applicable state and local income tax purposes following the IPO and Organizational Transactions. As an entity classified as a partnership for tax purposes, Rani LLC is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by Rani LLC is passed through to, and included in the taxable income or loss of its members, including the Company. The Company is taxed as a corporation and pays corporate federal, state and local taxes with respect to income allocated to the Company, based on the Company's economic interest in Rani LLC. The Company's tax provision also includes the activity of RMS, which is taxed as a corporation for federal and state income tax purposes. The Company anticipates this structure to remain in existence for the foreseeable future. The Company’s effective income tax rate was ( 0.22 )% and ( 0.21 )% for the three and nine months ended September 30, 2021 , respectively, and ( 0.21 )% for the three and nine months ended September 30, 2020. The Company has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more-likely-than-not that the deferred tax assets will not be realized. There were no material changes to uncertain tax positions for the three and nine months ended September 30, 2021 and 2020, and the Company does not anticipate material changes within the next 12 months. The Company is party to a TRA with the Continuing LLC Owners (Note 2). As there have been no transactions which have occurred which would trigger a liability under this agreement, the Company has no t recognized any deferred tax assets or liabilities related to this agreement as of September 30, 2021 |
Long Term Debt
Long Term Debt | 9 Months Ended |
Sep. 30, 2021 | |
Debt Disclosure [Abstract] | |
Long-term Debt | 11. Long-Term Debt Convertible Notes In September 2020, Rani LLC, entered into a secured convertible loan agreement (the “Loan and Security Agreement” or the “Loan”) with Avenue Venture Opportunity Fund L.P. (“Avenue”), whereby Rani LLC could borrow up to a maximum of $ 10.0 million, with $ 3.0 million being immediately available. The remaining $ 7.0 million available could be borrowed if Avenue received evidence of at least $ 40.0 million of net cash proceeds from the sale or issuance of securities to existing investors, or upfront payments in connection with strategic partnerships by March 31, 2021. Rani LLC opted not to draw down this additional amount, and the option has since expired undrawn. In exchange for access to this facility, Rani LLC agreed to issue warrants exercisable into Rani LLC preferred units amounting to $ 0.9 million; Rani LLC subsequently granted 118,929 Series E warrants with an exercise price of $ 7.1471 per unit (Note 7). The Loan was interest only until September 2021 and bore interest at a variable rate of interest per annum, compounded monthly until its maturity date of September 2023 , at which time all outstanding principal and interest would have become due and payable in cash if not already converted. Rani LLC’s obligations under the Loan were secured by a first priority security interest in substantially all of its assets. The Loan included customary events of default, including instances of a material adverse change in the Rani LLC’s operations, which may require prepayment of the outstanding Loan. At December 31, 2020 the effective interest rate on the Loan was 20.56 %. At September 30, 2021 there was no Loan outstanding. The Loan contained a contingent interest feature in the event of default that was not clearly and closely related to the underlying note and met the definition of a derivative. The Company concluded that the fair value of this derivative was insignificant for all periods presented. The Loan and Security Agreement contained negative and affirmative covenants, including covenants that restricted the ability of Rani LLC and its current and future subsidiaries' ability to, among other things, incur or prepay existing indebtedness, pay dividends or distributions, dispose of assets, engage in mergers and consolidations, make acquisitions or other investments, and make changes in the nature of the business. The Loan and Security Agreement also contained certain objective events of default, including, without limitation, nonpayment of principal, interest or other obligations, violation of the covenants, insolvency, court ordered judgments, and change in control. The Loan and Security Agreement required Rani LLC to provide audited consolidated financial statements to the lenders no later than 120 days after year-end. In July 2021, the Company repaid, in full, the $ 3.0 million of principal and approximately $ 0.5 million of final payment and fees under the Loan and Security Agreement resulting in a $ 0.7 million loss on extinguishment of debt recorded in the Company's condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2021. Avenue Capital also waived their right to convert the outstanding principal into Series E Preferred Units. Paycheck Protection Program Loan In April 2020, the Company received a $ 1.3 million small business loan under the Paycheck Protection Program (“PPP Loan”) as part of the CARES Act. The PPP Loan was due to mature in April 2022 , and bore interest at a rate of 1.0 % per annum. The PPP Loan was evidenced by a promissory note, which contained customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. The PPP Loan could be prepaid at any time prior to maturity with no prepayment penalties. The Company used all proceeds from the PPP Loan to retain employees, maintain payroll and make lease and utility payments. In September 2021, the Company repaid in full the $ 1.3 million of principal and interest related to the PPP Loan. |
Net Loss Per Share
Net Loss Per Share | 9 Months Ended |
Sep. 30, 2021 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | 13. Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per Class A common share attributable to Rani Therapeutics Holding, Inc. (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2021 2021 Numerator: Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc. $ ( 3,142 ) $ ( 3,142 ) Denominator: Weighted average Class A common share outstanding—basic and diluted 19,437 19,437 Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc.—basic and diluted $ ( 0.16 ) $ ( 0.16 ) The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per Class A common share attributable to Rani Therapeutics Holding, Inc.: Nine Months Ended September 30, 2021 Paired Interests 29,290,391 Stock options 2,119,524 Class A Units of Rani LLC exchangeable for Class A common stock 1,545,811 Restricted stock units 597,500 Restricted stock awards 119,915 33,673,141 Shares of Class B Common Stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. The outstanding shares of Class B Common Stock were determined to be antidilutive for the three and nine months ended September 30, 2021. Therefore, they are not included in the computation of net loss per Class A common share attributable to Rani Therapeutics Holding, Inc. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company operates and controls all of the business and affairs of Rani LLC, and through Rani LLC and its subsidiary, conducts its business. Because the Company manages and operates the business and controls the strategic decisions and day-to-day operations of Rani LLC and also has a substantial financial interest in Rani LLC, the Company consolidates the financial results of Rani LLC, and a portion of its net loss is allocated to the non-controlling interests in Rani LLC held by the Continuing LLC Owners. All intercompany accounts and transactions have been eliminated in consolidation. The Organizational Transactions were considered transactions between entities under common control. As a result, the condensed consolidated financial statements for periods prior to the IPO and the Organizational Transactions have been adjusted to combine the previously separate entities for presentation purposes. |
Unaudited Interim Financial Information | Unaudited Interim Financial Information The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of our operations and cash flows for interim periods in accordance with U.S. GAAP. All such adjustments are of a normal, recurring nature. Operating results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any future period. The consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these interim condensed financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company's Registration Statement on Form S-1 (No. 333-257809) filed with the SEC. |
Variable Interest Entities | Variable Interest Entities The Company consolidates all entities that it controls through a majority voting interest or as the primary beneficiary of a variable interest entity (“VIE”). In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company’s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation event. |
Use of Estimates | Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Estimates include, but are not limited to, revenue recognition, recovery of long-lived assets, equity-based compensation, accrued research and development costs and the fair value of Profits Interests and preferred unit warrants. Actual results may differ materially and adversely from these estimates. |
Revenue Recognition | Revenue Recognition The Company enters into evaluation arrangements with certain pharmaceutical partners, under which the Company performs evaluation services of the partner’s drug molecules using the RaniPill capsule. Revenue is recognized when control of promised goods or services is transferred to a customer in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for its arrangements with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Revenue for an individual contract is recognized at the related transaction price, which is the amount the Company expects to be entitled to in exchange for transferring these services. The terms of the evaluation services agreements usually include payments for evaluation services and evaluation milestones based on a decision to extend the agreement. The transaction price of the evaluation services contracts may include variable consideration. Application of the constraint for variable consideration requires judgment. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. For arrangements where the anticipated period between timing of transfer of services and the timing of payment is one year or less, the Company has elected to not assess whether a significant financing component exists. The Company recognizes evaluation services revenue over the period in which evaluation services are provided. Specifically, the Company recognizes revenue using an output method to measure progress, using samples processed relative to total expected samples to be processed as its measure of progress. For services under these arrangements, costs incurred are included in research and development expenses in the Company’s consolidated statements of operations and comprehensive loss. Customer options, such as options granted to allow a customer to acquire later stage evaluation services, are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes. Revenue is recognized for each distinct performance obligation as control is transferred to the customer. The Company recognizes revenue from its evaluation services over time as services are delivered, using a cost-based input method of revenue recognition over the contract term. The cost-based input measured is based on an estimate of total costs to be incurred to deliver the services over the contract period compared to costs incurred to date for each contract. The Company’s evaluation of estimated costs to perform the services typically includes estimates for effort related to contracted research, formulation, and animal testing. These estimates are based on the Company’s reasonable assumptions and its historical experience. Actual results may differ materially and adversely from these estimates. Incremental costs of obtaining contracts are expensed when incurred when the amortization period of the assets that otherwise would have been recognized is one year or less. To date none of these costs have been material. The costs to fulfill the contracts are determined to be immaterial and are recognized as an expense when incurred. Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract receivable when it has an unconditional right to consideration. No contract assets balance was recorded as of September 30, 2021 or December 31, 2020. Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of performance or where the Company has unsatisfied performance obligations. As of December 31, 2020 the Company had deferred revenue of $ 2.7 million. There was no deferred revenue as of September 30, 2021 . |
Concentrations of Credit Risk and Other Risks and Uncertainties | Concentrations of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions in excess of federally insured limits. The Company also holds money market funds that are not federally insured. However, management believes the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which these deposits are held and of the money market funds and other entities in which these investments are made. In December 2019, a novel strain of coronavirus, which causes the disease known as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 coronavirus has spread globally. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The COVID-19 pandemic has impacted and may continue to impact the Company’s third-party manufacturers and suppliers, which could disrupt its supply chain or the availability or cost of materials. The effects of the public health directives and the Company’s work-from-home policies may negatively impact productivity, disrupt its business, and delay clinical programs and timelines and future clinical trials, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct business in the ordinary course. These and similar, and perhaps more severe, disruptions in the Company’s operations could negatively impact business, results of operations and financial condition, including its ability to obtain financing. To date, the Company has not incurred impairment losses in the carrying values of its assets as a result of the pandemic and is not aware of any specific related event or circumstances that would require the Company to revise its estimates reflected in these condensed consolidated financial statements. The Company cannot be certain what the overall impact of the COVID-19 pandemic will be on its business and prospects. The extent to which the COVID-19 pandemic will further directly or indirectly impact its business, results of operations, financial condition, and liquidity, including planned and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related effects. In addition, the Company could see some limitations on employee resources that would otherwise be focused on its operation, including but not limited to sickness of employees or their families, the desire of employees to avoid contact with large groups of people, and increased reliance on working from home. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s business, financial condition, results of operations and prospects may be adversely affected. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying values of the Company’s cash equivalents, prepaid expenses, accounts payable, and accruals approximate their fair value due to their short-term nature. The fair value of the Company’s long-term debt approximated its carrying value based on borrowing rates currently available to the Company for debt with similar terms and maturities (Level 2 inputs). To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized in Level 3 (Note 3). A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument. |
Research and Development Costs | Research and Development Costs Research and development costs are expensed as incurred. Research and development expenses consist primarily of contract research fees and process development, outsourced labor and related expenses for personnel, facilities cost, fees paid to consultants and advisors, depreciation and supplies used in research and development and costs incurred under our evaluation agreements. Payments made prior to the receipt of goods or services to be used in research and development activities are recorded as prepaid expenses until the related goods or services are received. Until future commercialization is considered probable and the future economic benefit is expected to be realized the Company does not capitalize pre-launch inventory costs. Costs of property and equipment related to scaling-up of the manufacturing capacity for clinical trials and to support commercialization are capitalized as property and equipment unless the related asset does not have an alternative future use. Clinical and preclinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services. |
Equity-Based Compensation | Equity-Based Compensation Stock-Based Compensation In July 2021, the Company adopted and its stockholders approved, the Rani Therapeutics Holdings, Inc. 2021 Equity Incentive Plan (the “2021 Plan”). The Company has subsequently granted stock options to purchase shares of its Class A common stock as well as restricted stock units (“RSUs”) and restricted stock awards ("RSAs") from the 2021 Plan to both employees and non-employees. The Company measures stock-based compensation at fair value on the grant date of the award. The fair value of employee and nonemployee RSUs is determined based on the number of shares granted and the closing market price of the Company’s Class A common stock on the date of grant. The fair value of employee RSA's is determined based on the estimated fair value of the Company’s Class A common stock on the grant date and is subject to the Company's reacquisition right which is accounted for as a forfeiture provision (Note 9). For awards that vest subject to the satisfaction of service requirements, compensation expense is measured based on the fair value of the award on the date of grant and expense is recognized on a straight-line basis over the requisite service period. The Company accounts for forfeitures as they occur. Stock-based compensation is classified in the accompanying condensed consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. The Company determines the grant-date fair value of options to purchase common shares using the Black-Scholes option-pricing model which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company’s expected dividend yield . Such assumptions represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. If actual results are not consistent with the Company’s assumptions and judgments used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company’s consolidated results of operations. Unit-Based Compensation Prior to the IPO, Rani LLC had granted equity-based awards to employees, Board Managers and nonemployees, including ICL employees and consultants, in the form of non-vested incentive units (“Profits Interests”) and/or options to purchase common units. All awards of Profits Interests and options to purchase common units were measured based on the estimated fair value of the award on the date of grant. Forfeitures were recognized when they occurred. All of the Profits Interests were subject to service and performance-based conditions and the Company evaluated the probability of achieving each performance-based condition at each reporting date and recognized equity-based compensation expense for employee and consultant awards and distributions of equity for ICL employee awards in the condensed consolidated financial statements when it was deemed probable that the performance-based condition would be met using the accelerated attribution method over the requisite service period. The options to purchase common units were subject to service conditions and generally vested over three or four years. The Company utilized estimates and assumptions in determining the fair value of its Profits Interests and options to purchase common units on the date of grant. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation , to estimate the fair value of its preferred units, common units and Profits Interests. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include several objective and subjective factors, including probability weighting of events, volatility, time to an exit event, a risk-free interest rate, the prices at which the Company sold preferred units, the superior rights, and preferences of the preferred units senior to the Company’s common units at the time, and a discount for the lack of marketability. Changes to the key assumptions used in the valuations could result in different fair values at each valuation date. |
Tax Receivable Agreement | Tax Receivable Agreement In August 2021, in connection with the IPO and Organizational Transactions, the Company entered into a tax receivable agreement ("TRA") with certain of the Continuing LLC Owners. The TRA provides that the Company pay to such Continuing LLC Owners, 85 % of the amount of tax benefits, if any, it is deemed to realize (calculated using certain assumptions) as a result of (i) increases in the tax basis of assets of Rani LLC resulting from (a) any future redemptions or exchanges of Paired Interests and (b) payments under the TRA and (ii) certain other benefits arising from payments under the TRA (collectively the “Tax Attributes”). A liability for the payable to parties subject to the TRA, and a reduction to stockholders’ equity, is accrued when (i) an exchange of a Paired Interest has occurred and (ii) when it is deemed probable that the Tax Attributes associated with the exchange will be used to reduce the Company’s taxable income based on the contractual percentage of the benefit of Tax Attributes that the Company expects to receive over a period of time. No exchanges of Paired Interests had occurred through September 30, 2021 and therefore no liability had been accrued for the TRA. |
Comprehensive Loss | Comprehensive Loss Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions and other events and/or circumstances from non-owner sources. The Company did not have any other comprehensive loss for any of the periods presented, and therefore comprehensive loss was the same as the Company’s net loss. |
Net Loss Per Class A Common Share Attributable to Rani Therapeutics Holdings, Inc. | Net Loss Per Class A Common Share Attributable to Rani Therapeutics Holdings, Inc. Basic net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. is computed by dividing net loss attributable to the Company by the weighted average number of Class A Common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per Class A Common share is computed giving effect to all potentially dilutive shares. Diluted net loss per Class A Common share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. Net loss per share is not presented for the three and nine months ended September 30, 2020 as the Company did not have any economic interests prior to the date of the IPO and Organizational Transactions through which it was given ownership in Rani LLC. Losses prior to the IPO and Organizational Transactions would have been allocated to the original members of Rani LLC. The basic and diluted net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc. for the three and nine-months ended September 30, 2021 is applicable only for the period from August 4, 2021 to September 30, 2021, which is the period following the IPO and Organizational Transactions and represents the period that the Company had Class A common shares outstanding. |
Non-controlling Interest | Non-Controlling Interest Non-controlling interest ("NCI") represents the portion of income or loss, net assets and comprehensive loss of our consolidated subsidiary that is not allocable to the Company based on the Company's percentage of ownership of Rani LLC. In August 2021, based on the Organizational Transactions, the Company became the sole managing member of Rani LLC. As of September 30, 2021, the Company held approximately 39 % of the Class A Units of Rani LLC, and approximately 61 % of the outstanding Class A Units of Rani LLC are held by the Continuing LLC Owners. Therefore, the Company reports NCI based on the Class A Units of Rani LLC held by the Continuing LLC Owners on its condensed consolidated balance sheet as of September 30, 2021. Income or loss attributed to the NCI in Rani LLC is based on the Class A Units outstanding during the period for which the income or loss is generated and is presented on the condensed consolidated statements of operations and comprehensive income or loss. Future exchanges of Paired Interests will result in a change in ownership and reduce or increase the amount recorded as NCI and increase or decrease additional paid-in-capital when Rani LLC has positive or negative net assets, respectively. From the date of the Organizational Transactions to September 30, 2021, there were no exchanges of Paired Interests. |
New Accounting Pronouncements | New Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-02, Leases (“Topic 842”), as subsequently amended, to improve financial reporting and disclosures about leasing transactions. Topic 842 requires companies that lease assets to recognize on the condensed consolidated balance sheet the assets and liabilities for the rights and obligations created by those leases, where the lease terms exceed 12 months. The recognition, measurement, and presentation of expense and cash flows arising from a lease by a lessee will depend primarily on its classification as a finance or operating lease; both types of leases will be recognized on the condensed consolidated balance sheet. Topic 842 also requires disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. On June 3, 2020, the FASB amended the effective dates of Topic 842 to give immediate relief from business disruptions caused by the COVID-19 pandemic and provided a one-year deferral of the effective date for nonpublic companies. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, and assuming the Company continues to be considered an emerging growth company, Topic 842 will be effective for the Company on January 1, 2022. The Company has not yet determined the effects of Topic 842 on its condensed consolidated financial statements but does expect the adoption of Topic 842 will have a material impact on the Company’s consolidated financial statements and related notes to the recognition of right of use (“ROU”) assets and lease liabilities on the Company’s consolidated balance sheets, but it will not have a material impact on the Company’s consolidated statement of income. The adoption of Topic 842 will also result in enhanced disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (“ASU 2016-13”) to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, and assuming the Company continues to be considered an emerging growth company, ASU 2016-13 will be effective for the Company on January 1, 2023. The Company has not yet determined the potential effects of ASU 2016-13 on its condensed consolidated financial statements and disclosures. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Schedule of Assets and Liabilities Recorded at Fair Value on a Recurring Basis | The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of inputs used in such measurements (in thousands): As of September 30, 2021 Level 1 Level 2 Level 3 Assets: Money market funds $ 126,363 $ — $ — Total assets $ 126,363 $ — $ — As of December 31, 2020 Level 1 Level 2 Level 3 Assets: Money market funds $ 71,666 $ — $ — Total assets $ 71,666 $ — $ — Liabilities: Preferred unit warrant liability $ — $ — $ 320 Total liabilities $ — $ — $ 320 |
Summary of the Changes in the Fair Value of the Company’s Liability | The following tables set forth a summary of the changes in the fair value of the Company’s liability measured using Level 3 inputs (in thousands): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Balance at beginning of period $ 606 $ — $ 320 $ 655 Change in estimated fair value of Series B warrants — — — 16 Change in estimated fair value of Series E warrants 85 — 371 — Expiration of Series B warrants — — — ( 671 ) Settlement of Series E warrants ( 691 ) ( 691 ) Balance at end of period $ — $ — $ — $ — |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Accrued Liabilities [Abstract] | |
Schedule of Accrued Expenses | Accrued expenses consist of the following (in thousands): September 30, December 31, 2021 2020 Accrued professional fees $ 379 $ — Payroll and related 1,951 136 IPO issuance costs 570 — Other 749 414 Total accrued expenses $ 3,649 $ 550 |
Evaluation Agreements (Tables)
Evaluation Agreements (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Evaluation Agreements [Abstract] | |
Schedule of deferred revenue balance | Changes in the deferred revenue balance are as follows (in thousands): September 30, December 31, 2021 2020 Balance at beginning of period $ 2,717 $ 179 Additions — 3,000 Deductions ( 2,717 ) ( 462 ) Balance at end of period $ — $ 2,717 |
Related Party Transactions (Tab
Related Party Transactions (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Related Party Transactions [Abstract] | |
Schedule of Amounts Charged for Services and Rent | The table below details the amounts charged by ICL for services and rent, net of the amount that RMS charged ICL, which is included in the condensed consolidated statements of operations and comprehensive loss (in thousa nds): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Research and development $ 222 $ ( 22 ) $ 377 $ 98 General and administrative 149 174 516 625 Total $ 371 $ 152 $ 893 $ 723 |
Equity Based Compensation (Tabl
Equity Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Summary of Stock Options and Options for Common Units Activity | A summary of options for common units activity during the periods indicated is as follows: Number of Unit Option Awards Weighted Average Exercise Price Weighted Aggregate Intrinsic Value (in thousands) Balance at December 31, 2020 — — — Granted 2,292,309 4.99 9.89 Canceled and replaced with stock options ( 2,292,309 ) 4.99 9.89 Balance at September 30, 2021 — — — — |
Summary of Restricted Stock Unit and Award Activity | A summary of RSU activity during the periods indicated is as follows: Number of Restricted Stock Units Weighted Average Grant-Date Fair Value per Share Balance at December 31, 2020 — — Granted 599,500 $ 19.56 Forfeited ( 2,000 ) $ 19.56 Balance at September 30, 2021 597,500 $ 19.56 A summary of RSA activity during the periods indicated is as follows: Number of Restricted Stock Awards Weighted Average Grant-Date Fair Value per Share Balance at December 31, 2020 — — Granted as replacement of Profits Interests 137,691 $ 5.78 Vested ( 15,058 ) $ 5.72 Forfeited ( 2,718 ) $ 6.11 Balance at September 30, 2021 119,915 $ 5.79 |
Summary of Profits Interests Activity | A summary of Profits Interests activity during the periods indicated is as follows: Number of Weighted Profits Balance at December 31, 2020 6,926,358 $ 1.63 $ 1.44 - $ 2.29 Granted 1,857,000 $ 2.13 $ 1.99 - $ 2.13 Forfeited ( 235,957 ) $ 2.04 $ 1.45 - $ 2.29 Vested ( 8,149,901 ) $ 1.70 $ 1.44 - $ 2.29 Canceled and replaced with restricted stock awards ( 397,500 ) $ 2.13 $ 1.99 - $ 2.13 Balance at September 30, 2021 — $ — |
Summary of Components of Equity-based Compensation Expense | The following table summarizes the components of equity-based compensation expense resulting from the grant of stock options, RSUs, RSAs, Profits Interests, and options for common units, recorded in the Company’s condensed consolidated statement of operations and comprehensive loss (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 6,635 — $ 6,696 — General and administrative 12,061 — 12,282 — Total equity-based compensation $ 18,696 — $ 18,978 — |
Stock Options [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Summary of Stock Options and Options for Common Units Activity | A summary of stock option activity during the periods indicated is as follows: Number of Stock Option Awards Weighted Average Exercise Price Weighted Aggregate Intrinsic Value (in thousands) Balance at December 31, 2020 — — — Granted as replacement awards 1,212,124 $ 9.44 9.72 $ 10,158 Granted 907,400 $ 17.84 9.92 $ 1,244 Balance at September 30, 2021 2,119,524 $ 13.04 9.81 $ 11,402 Exercisable at September 30, 2021 57,806 $ 9.44 9.72 $ 484 Nonvested at September 30, 2021 2,061,718 $ 13.14 9.81 $ 10,918 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per Class A common share attributable to Rani Therapeutics Holding, Inc.: Nine Months Ended September 30, 2021 Paired Interests 29,290,391 Stock options 2,119,524 Class A Units of Rani LLC exchangeable for Class A common stock 1,545,811 Restricted stock units 597,500 Restricted stock awards 119,915 33,673,141 |
Organization and Nature of Bu_2
Organization and Nature of Business - Additional Information (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||
Aug. 31, 2021USD ($)$ / sharesshares | Jul. 31, 2021shares | Sep. 30, 2021USD ($)shares | Sep. 30, 2020USD ($) | Jun. 30, 2020USD ($) | Mar. 31, 2020USD ($) | Sep. 30, 2021USD ($)Segmentshares | Sep. 30, 2020USD ($) | Dec. 31, 2020USD ($) | |
Proceeds from issuance from initial public offering | $ 73,600 | ||||||||
Common Stock, Voting Rights | Holders of Class A common stock are entitled to one vote per share; holders of Class B common stock are entitled to ten votes per share; and holders of Class C common stock have no voting rights. Except as otherwise expressly provided in the Amended and Restated Certificate of Incorporation or as required by law, the holders of Class A common stock and Class B common stock (and, on any matter on which the Class C common stock or the holders of preferred stock are entitled to vote with the Class A common stock and the Class B common stock, the Class C common stock and the preferred stock) will vote together as a single class and not as separate series or classes. | ||||||||
Net loss | $ (28,700) | $ (2,883) | $ (39,783) | $ (10,947) | |||||
Net loss attributable to Rani Therapeutics Holdings, Inc. | (3,142) | $ (2,883) | $ (2,714) | $ (5,350) | (3,142) | ||||
Accumulated deficit | 3,142 | 3,142 | $ 114,003 | ||||||
Operating activities, net | 20,796 | 8,260 | |||||||
Cash and cash equivalents | 129,700 | $ 129,700 | |||||||
Number of operating segment | Segment | 1 | ||||||||
IPO | |||||||||
Net loss attributable to Rani Therapeutics Holdings, Inc. | $ (382) | ||||||||
Common Class A [Member] | |||||||||
Proceeds from issuance from initial public offering | $ 74,218 | $ 0 | |||||||
Exchange Of Common Units | shares | 854,807 | 854,807 | |||||||
Common Class A [Member] | IPO | |||||||||
Issuance of common stock, shares | shares | 7,666,667 | 7,667,000 | |||||||
Parent Company [Member] | |||||||||
Date of incorporation | Apr. 6, 2021 | ||||||||
Parent Company [Member] | Common Class A [Member] | |||||||||
Issuance of common stock, shares | shares | 7,666,667 | ||||||||
Common Stock, Voting Rights | Class A common stock, each share of which entitles its holders to one vote per share | ||||||||
Common stock, conversion basis | In connection with the closing of the IPO, each LLC interest was exchanged 1 for 0.5282 as determined and predicated on the initial public offering price of the Company’s Class A common stock. | the remaining 64,475 Class A Units of Rani LLC continue to be outstanding and are exchangeable for the Company's Class A common stock at the option of the ICL Holders. | |||||||
Exchange Of Common Units | shares | 12,047,925 | 1,655,409 | 1,655,409 | ||||||
Parent Company [Member] | Common Class A [Member] | IPO | |||||||||
Issuance of common stock, shares | shares | 7,666,667 | ||||||||
Stock offering price per share | $ / shares | $ 11 | ||||||||
Parent Company [Member] | Common Class B [Member] | |||||||||
Issuance of common stock, shares | shares | 29,290,391 | ||||||||
Common Stock, Voting Rights | Class B common stock, each share of which entitles its holders to 10 votes per share on all matters presented to the Company's stockholders | ||||||||
Parent Company [Member] | Common Class C [Member] | |||||||||
Common Stock, Voting Rights | Class C common stock, which has no voting rights, except as otherwise required by law |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands | 9 Months Ended | |||
Sep. 30, 2021 | Aug. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Summary Of Significant Accounting Policies [Line Items] | ||||
Contract assets | $ 0 | $ 0 | ||
Deferred revenue | $ 0 | $ 2,717 | $ 179 | |
Continuing LLC Owners [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Percentage of tax benefit to be transferred | 85.00% | |||
Capital Unit, Class A [Member] | Continuing LLC Owners [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
General Partner Ownership Interest | 39.00% | |||
Outstanding Capital Class A Unit [Member] | Continuing LLC Owners [Member] | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
General Partner Ownership Interest | 61.00% |
Fair Value Measurements - Finan
Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Liabilities: | ||
Total liabilities | $ 0 | |
Level 1 | ||
Assets: | ||
Total assets | 126,363 | $ 71,666 |
Liabilities: | ||
Total liabilities | 0 | |
Level 1 | Money market funds | ||
Assets: | ||
Total assets | 126,363 | 71,666 |
Level 1 | Preferred unit warrant liability | ||
Liabilities: | ||
Total liabilities | 0 | |
Level 2 | ||
Assets: | ||
Total assets | 0 | 0 |
Liabilities: | ||
Total liabilities | 0 | |
Level 2 | Money market funds | ||
Assets: | ||
Total assets | 0 | 0 |
Level 2 | Preferred unit warrant liability | ||
Liabilities: | ||
Total liabilities | 0 | |
Level 3 | ||
Assets: | ||
Total assets | 0 | 0 |
Liabilities: | ||
Total liabilities | 320 | |
Level 3 | Money market funds | ||
Assets: | ||
Total assets | $ 0 | 0 |
Level 3 | Preferred unit warrant liability | ||
Liabilities: | ||
Total liabilities | $ 320 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) $ in Thousands | Sep. 30, 2021USD ($) |
Fair Value, Recurring | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Financial liabilities measured at fair value | $ 0 |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of the changes in the fair value of the Liability (Details) - Level 3 - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Balance at beginning of period | $ 606 | $ 0 | $ 320 | $ 655 |
Expiration of Series B warrants | 0 | 0 | 0 | (671) |
Settlement of Series E warrant | (691) | (691) | ||
Balance at end of period | 0 | 0 | 0 | 0 |
Series B Warrants | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Change in estimated fair value | 0 | 0 | 0 | 16 |
Series E Warrants | ||||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||||
Change in estimated fair value | $ 85 | $ 0 | $ 371 | $ 0 |
Accrued Expenses - Schedule of
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Accrued Liabilities [Abstract] | ||
Accrued professional fees | $ 379 | $ 0 |
Payroll and related | 1,951 | 136 |
Deferred financing costs | 570 | 0 |
Other | 749 | 414 |
Total accrued expenses | $ 3,649 | $ 550 |
Evaluation Agreements - Additio
Evaluation Agreements - Additional information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||||
Nov. 30, 2017 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | May 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Disaggregation of Revenue [Line Items] | ||||||||
Deferred revenue | $ 0 | $ 0 | $ 2,717,000 | $ 179,000 | ||||
Receivables or net contract assets from agreement | 0 | 0 | 0 | |||||
Takeda Agreement [Member] | ||||||||
Disaggregation of Revenue [Line Items] | ||||||||
Upfront payment | $ 5,900,000 | |||||||
Amount payable for evaluation services | $ 3,000,000 | |||||||
Agreement termination period | 30 days | |||||||
Agreement termination negotiation period | 120 days | |||||||
Revenue from contract | $ 0 | $ 100,000 | $ 2,700,000 | $ 300,000 | ||||
Deferred revenue | $ 2,000,000 | $ 2,700,000 |
Evaluation Agreements - Schedul
Evaluation Agreements - Schedule of deferred revenue balance (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended |
Sep. 30, 2021 | Dec. 31, 2020 | |
Evaluation Agreements [Abstract] | ||
Balance at beginning of period | $ 2,717 | $ 179 |
Additions | 0 | 3,000 |
Deductions | (2,717) | (462) |
Balance at end of period | $ 0 | $ 2,717 |
Related Party Transactions - Ad
Related Party Transactions - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Aug. 31, 2021 | Feb. 28, 2021 | Jun. 30, 2017 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2017 | |
Related Party Transaction [Line Items] | |||||||
Outstanding net advances | $ 1,720 | $ 0 | |||||
Aggregate desired patent acquisition | 1,000 | ||||||
Proceeds from Issuance of Common Stock | 71,100 | ||||||
Legacy Cost | $ 200 | ||||||
Equity-based compensation expense | $ 19,431 | 0 | |||||
Number of Options, Canceled and replaced | (2,292,309) | ||||||
Rani Therapeutics Holdings Inc. [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Number of Options, Canceled and replaced | 2,292,309 | ||||||
Secondary Sales Transactions | |||||||
Related Party Transaction [Line Items] | |||||||
Sale of common units | 210,000 | ||||||
Common unit, price per share | $ 7.1471 | ||||||
Equity-based compensation expense | $ 500 | ||||||
Sales price and fair value of common units, difference | 500 | ||||||
Common Class A [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Common stock units issued | 19,712,000 | ||||||
Exchange of common units | 854,807 | ||||||
Common Class A [Member] | Rani Therapeutics Holdings Inc. [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Conversion of stock, shares | 1,545,811 | ||||||
Issuance of common stock, shares | 7,666,667 | ||||||
Number of Options, Canceled and replaced | 919,282 | ||||||
Common stock, conversion basis | In connection with the closing of the IPO, each LLC interest was exchanged 1 for 0.5282 as determined and predicated on the initial public offering price of the Company’s Class A common stock. | the remaining 64,475 Class A Units of Rani LLC continue to be outstanding and are exchangeable for the Company's Class A common stock at the option of the ICL Holders. | |||||
Exchange of common units | 12,047,925 | 1,655,409 | |||||
Series D Units | |||||||
Related Party Transaction [Line Items] | |||||||
Conversion of stock, amount | $ 1,000 | ||||||
Research and Development Expense | Secondary Sales Transactions | |||||||
Related Party Transaction [Line Items] | |||||||
Equity-based compensation expense | 300 | ||||||
General and Administrative Expense | Secondary Sales Transactions | |||||||
Related Party Transaction [Line Items] | |||||||
Equity-based compensation expense | $ 200 | ||||||
ICL | |||||||
Related Party Transaction [Line Items] | |||||||
Outstanding net advances | $ 6,600 | ||||||
Interest rate on notes | 1.97% | ||||||
Rate of loan fees payable upon demand | 2.75% | ||||||
Payment of interest and principal on notes receivable | 200 | ||||||
Notes receivable outstanding | $ 1,700 | ||||||
One time patent payment to related party | $ 300 | ||||||
ICL | Exclusive License Intellectual Property and Common Unit Purchase Agreement | |||||||
Related Party Transaction [Line Items] | |||||||
Common stock units issued | 46,000,000 | ||||||
ICL | Series B Convertible Preferred Units | |||||||
Related Party Transaction [Line Items] | |||||||
Conversion of stock, shares | 51,341 | ||||||
ICL | Series D Units | |||||||
Related Party Transaction [Line Items] | |||||||
Conversion of stock, shares | 59,312 | ||||||
ICL | Research and Development Expense | |||||||
Related Party Transaction [Line Items] | |||||||
Amount charged to related party | $ 500 | $ 300 | |||||
RMS-ICL | |||||||
Related Party Transaction [Line Items] | |||||||
Service agreement term | In June 2021, RMS entered into the RMS-ICL Service Agreement with ICL effective January 1, 2021 (the "RMS-ICL Service Agreement"), pursuant to which ICL agreed to rent a specified portion of its facility to RMS. Additionally, RMS and ICL agreed to provide personnel services to the other upon requests based on rates specified in the agreement. The RMS-ICL Service Agreement has a 12-month term and will automatically renew for successive 12-month periods unless terminated. For the nine months ended September 30, 2020 and 2021, RMS charged ICL $0.3 million and $0.5 million for services performed, respectively, and such amounts charged were recorded as a reduction to research and development expense in the condensed consolidated statement of operations and comprehensive loss. | ||||||
South Lake One LLC and Affiliates | Common Class A [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Conversion of stock, shares | 5,277,729 | ||||||
Issuance of common stock, shares | 6,458,904 | ||||||
South Lake One LLC and Affiliates | Series E Preferred Units [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Issuance of common stock, shares | 7,880,120 | ||||||
Common unit, price per share | $ 7.1471 |
Related Party Transactions - Sc
Related Party Transactions - Schedule of Amounts Charged for Services and Rent (Details) - ICL - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Related Party Transaction [Line Items] | ||||
Related party charges | $ 371 | $ 152 | $ 893 | $ 723 |
Research and Development Expense | ||||
Related Party Transaction [Line Items] | ||||
Related party charges | 222 | (22) | 377 | 98 |
General and Administrative Expense | ||||
Related Party Transaction [Line Items] | ||||
Related party charges | $ 149 | $ 174 | $ 516 | $ 625 |
Warrants - Additional Informati
Warrants - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Aug. 31, 2021 | Jan. 31, 2021 | Sep. 30, 2021 | Dec. 31, 2017 | Jul. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | |
Preferred Unit Warrants | Series E Preferred Units | Loan and Security Agreement | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Securities purchase in exchange for warrant | 118,929 | ||||||
Warrants exercisable period | 7 years | ||||||
Warrant exercise price | $ 7.1471 | ||||||
Preferred Unit Warrants | Rani Therapeutics Holdings Inc. [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Common Stock, Units Exchanged | 62,887 | ||||||
Common Unit Warrants | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Warrants exercisable period | 5 years | ||||||
Warrant exercise price | $ 2.18 | $ 2.18 | $ 2.18 | ||||
Class of warrant or right, outstanding | 0 | 229,315 | |||||
Common unit warrants issued | 229,315 | ||||||
Issuance date fair value of warrants or right | $ 0.3 | ||||||
Warrants or rights exercised | 6,000 | ||||||
Common Unit Warrants | Rani Therapeutics Holdings Inc. [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Common Stock, Units Exchanged | 60,494 | ||||||
Series E Warrants [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Class of warrant or right, outstanding | 0 | 118,929 | |||||
Class A Units [Member] | IPO [Member] | Rani Therapeutics Holdings Inc. [Member] | |||||||
Class Of Warrant Or Right [Line Items] | |||||||
Warrants or rights exercised | 71,867 |
Stockholders' Equity_Members'_2
Stockholders' Equity/Members' Deficit - Additional Information (Details) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended | |
Aug. 31, 2021shares | Jul. 31, 2021USD ($)shares | Sep. 30, 2021$ / sharesshares | Sep. 30, 2021Vote$ / sharesshares | |
Preferred stock authorized | 20,000,000 | 20,000,000 | ||
Preferred stock, par value | $ / shares | $ 0.0001 | $ 0.0001 | ||
Common stock, voting rights | Holders of Class A common stock are entitled to one vote per share; holders of Class B common stock are entitled to ten votes per share; and holders of Class C common stock have no voting rights. Except as otherwise expressly provided in the Amended and Restated Certificate of Incorporation or as required by law, the holders of Class A common stock and Class B common stock (and, on any matter on which the Class C common stock or the holders of preferred stock are entitled to vote with the Class A common stock and the Class B common stock, the Class C common stock and the preferred stock) will vote together as a single class and not as separate series or classes. | |||
Previously Reported [Member] | ||||
Common units, authorized | 101,000,000 | 101,000,000 | ||
IPO | Rani LLC | ||||
Net proceeds from issuance from initial public offering | $ | $ 73.6 | |||
Convertible Preferred Units | Previously Reported [Member] | ||||
Common units reserved for issuance | 32,620,000 | 32,620,000 | ||
Common Class A | ||||
Common stock shares authorized | 800,000,000 | 800,000,000 | ||
Common stock par value | $ / shares | $ 0.0001 | $ 0.0001 | ||
Common stock, number of voting rights per share | Vote | 1 | |||
Common Class A | IPO | ||||
Issuance of common stock, shares | 7,666,667 | 7,667,000 | ||
Common stock purchased by underwriter | 1,000,000 | |||
Common Class B | ||||
Common stock shares authorized | 40,000,000 | 40,000,000 | ||
Common stock par value | $ / shares | $ 0.0001 | $ 0.0001 | ||
Common stock, number of voting rights per share | Vote | 10 | |||
Common Class B | Rani LLC | ||||
Issuance of common stock, shares | 29,290,391 | |||
Stock conversion ratio | 1 | |||
Common Class C [Member] | ||||
Common stock shares authorized | 20,000,000 | 20,000,000 | ||
Common stock par value | $ / shares | $ 0.0001 | $ 0.0001 | ||
Common stock, number of voting rights per share | Vote | 0 | |||
Profits Interests | Previously Reported [Member] | ||||
Common units reserved for issuance | 10,850,000 | 10,850,000 | ||
Common Unit | IPO | Rani LLC | ||||
Issuance of common stock, shares | 7,666,667 |
Equity-Based Compensation - Add
Equity-Based Compensation - Additional Information (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended | |
Aug. 31, 2021 | Jul. 31, 2021 | Sep. 30, 2021 | Sep. 30, 2021 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Number of Options, Canceled and replaced | (2,292,309) | |||
Additional common units | 2,000,000 | |||
Number of Profit Interests, Canceled and replaced with restricted stock | (397,500) | |||
Additional recognized compensation expense | $ 14 | |||
Incremental equity-based compensation expense | $ 3 | $ 3 | ||
IPO and Organizational Transactions, units of unvested Profits Interests | 1,771,767 | |||
Number of Options, Granted | 2,292,309 | |||
Stock Options [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Unrecognized equity-based compensation expense | 17.8 | $ 17.8 | ||
Recognized over a weighted-average period | 3 years 6 months | |||
Number of Options, Granted as replacement awards | 1,212,124 | |||
Number of Options, Granted | 907,400 | |||
Stock Options [Member] | Minimum | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Vesting period | 3 years | |||
Stock Options [Member] | Maximum | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Vesting period | 4 years | |||
Restricted Stock Units [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Unrecognized equity-based compensation expense | 11.4 | $ 11.4 | ||
Recognized over a weighted-average period | 1 year 10 months 24 days | |||
Restricted Stock | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Unrecognized equity-based compensation expense | $ 0.7 | $ 0.7 | ||
Recognized over a weighted-average period | 3 years 3 months 18 days | |||
Granted as replacement of Profits Interests, Number of Shares | 137,691 | |||
Common Class A | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Exchange of common units | 854,807 | 854,807 | ||
Common Class A | Restricted Stock | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Number of Options, Granted as replacement awards | 1,212,124 | |||
Granted as replacement of Profits Interests, Number of Shares | 137,691 | |||
Rani Therapeutics Holdings Inc. [Member] | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Number of Options, Canceled and replaced | 2,292,309 | |||
Number of Profit Interests, Canceled and replaced with restricted stock | 397,500 | |||
Number of Options, Granted | 2,292,309 | |||
Rani Therapeutics Holdings Inc. [Member] | Common Class A | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Number of Options, Canceled and replaced | 919,282 | |||
Exchange of common units | 12,047,925 | 1,655,409 | 1,655,409 | |
Common units holders | 3,201,220 | 3,201,220 | ||
Common unit conversion basis | In connection with the closing of the IPO, each LLC interest was exchanged 1 for 0.5282 as determined and predicated on the initial public offering price of the Company’s Class A common stock. | the remaining 64,475 Class A Units of Rani LLC continue to be outstanding and are exchangeable for the Company's Class A common stock at the option of the ICL Holders. | ||
Conversion of stock, shares | 1,545,811 | |||
Rani Therapeutics Holdings Inc. [Member] | Common Class A | 2021 Employee Stock Purchase Plan | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Shares reserved for future issuance | 500,000 | |||
Rani Therapeutics Holdings Inc. [Member] | Common Class A | 2021 Equity Incentive Plan | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Shares reserved for future issuance | 5,500,000 |
Equity-Based Compensation - Sum
Equity-Based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, $ in Thousands | 9 Months Ended |
Sep. 30, 2021USD ($)$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Number of Options, Outstanding, Beginning balance | shares | 0 |
Number of Options, Granted | shares | 2,292,309 |
Number of Options, Outstanding, Ending balance | shares | 0 |
Weighted Average Exercise Price per Share, Outstanding, Beginning balance | $ / shares | $ 0 |
Weighted Average Exercise Price per Share, Granted | $ / shares | 4.99 |
Weighted Average Exercise Price per Share, Outstanding, Ending balance | $ / shares | $ 0 |
Weighted Average Remaining Contractual Term, Granted (in years) | 9 years 10 months 20 days |
Stock Options [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Number of Options, Outstanding, Beginning balance | shares | 0 |
Number of Options, Granted as replacement awards | shares | 1,212,124 |
Number of Options, Granted | shares | 907,400 |
Number of Options, Outstanding, Ending balance | shares | 2,119,524 |
Exercisable at September 30, 2021 | shares | 57,806 |
Nonvested at September 30, 2021 | shares | 2,061,718 |
Weighted Average Exercise Price per Share, Outstanding, Beginning balance | $ / shares | $ 0 |
Weighted Average Exercise Price per Share, Granted as replacement awards | $ / shares | 9.44 |
Weighted Average Exercise Price per Share, Granted | $ / shares | 17.84 |
Weighted Average Exercise Price per Share, Outstanding, Ending balance | $ / shares | 13.04 |
Weighted Average Exercise Price per Share, Exercisable at September 30, 2021 | $ / shares | 9.44 |
Weighted Average Exercise Price per Share, Nonvested at September 30, 2021 | $ / shares | $ 13.14 |
Weighted Average Remaining Contractual Term, Granted as replacement awards (in years) | 9 years 8 months 19 days |
Weighted Average Remaining Contractual Term, Granted (in years) | 9 years 11 months 1 day |
Weighted Average Remaining Contractual Term (in years) | 9 years 9 months 21 days |
Weighted Average Remaining Contractual Term, Exercisable at September 30, 2021 (in years) | 9 years 8 months 19 days |
Weighted Average Remaining Contractual Term, Nonvested at September 30, 2021 (in years) | 9 years 9 months 21 days |
Aggregate Intrinsic Value, Outstanding, Beginning Balance | $ | $ 0 |
Aggregate Intrinsic Value, Granted as replacement awards (in thousands) | $ | 10,158 |
Aggregate Intrinsic Value, Granted (in thousands) | $ | 1,244 |
Aggregate Intrinsic Value, Outstanding, Ending Balance | $ | 11,402 |
Aggregate Intrinsic Value, Exercisable at September 30, 2021 (in thousands) | $ | 484 |
Aggregate Intrinsic Value, Nonvested at September 30, 2021 (in thousands) | $ | $ 10,918 |
Equity-Based Compensation - S_2
Equity-Based Compensation - Summary of Restricted Stock Unit and Award Activity (Details) | 9 Months Ended |
Sep. 30, 2021$ / sharesshares | |
Restricted Stock Units [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Outstanding, Number of Shares, Beginning Balance | 0 |
Granted, Number of Shares | 599,500 |
Forfeited, Number of Shares | (2,000) |
Outstanding, Number of Shares, Ending Balance | 597,500 |
Outstanding, Weighted-Average Grant Date Fair Value | $ / shares | $ 0 |
Granted, Weighted-Average Grant Date Fair Value | $ / shares | 19.56 |
Forfeited, Weighted-Average Grant Date Fair Value | $ / shares | 19.56 |
Outstanding, Weighted-Average Grant Date Fair Value | $ / shares | $ 19.56 |
Restricted Stock Awards | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Outstanding, Number of Shares, Beginning Balance | 0 |
Granted as replacement of Profits Interests, Number of Shares | 137,691 |
Vested, Number of Shares | (15,058) |
Forfeited, Number of Shares | (2,718) |
Outstanding, Number of Shares, Ending Balance | 119,915 |
Outstanding, Weighted-Average Grant Date Fair Value | $ / shares | $ 0 |
Granted as replacement of Profits Interests, Weighted-Average Grant Date Fair Value | 5.78 |
Vested, Weighted-Average Grant Date Fair Value | $ / shares | $ 5.72 |
Forfeited, Weighted-Average Grant Date Fair Value | $ / shares | 6.11 |
Outstanding, Weighted-Average Grant Date Fair Value | $ / shares | $ 5.79 |
Equity-Based Compensation - S_3
Equity-Based Compensation - Summary of Profits Interests Activity (Details) | 9 Months Ended |
Sep. 30, 2021$ / sharesshares | |
Number of Profit Interests, Balance at December 31, 2020 | shares | 6,926,358 |
Number of Profit Interests Granted | shares | 1,857,000 |
Number of Profit Interests Forfeited | shares | (235,957) |
Number of Profit Interests Vested | shares | (8,149,901) |
Number of Profit Interests, Canceled and replaced with restricted stock awards | shares | 397,500 |
Number of Profit Interests, Balance at September 30, 2021 | shares | 0 |
Weighted Average Grant Date Fair Value, Balance at December 31, 2020 | $ 1.63 |
Weighted Average Grant Date Fair Value, Granted | 2.13 |
Weighted Average Grant Date Fair Value, Forfeited | 2.04 |
Weighted Average Grant Date Fair Value, Vested | 1.70 |
Weighted Average Grant Date Fair Value, Canceled and replaced with restricted stock awards | 2.13 |
Weighted Average Grant Date Fair Value, Balance at September 30, 2021 | 0 |
Minimum [Member] | |
Profits Interests Threshold, Balance at December 31, 2020 | 1.44 |
Profits Interests Threshold, Granted | 1.99 |
Profits Interests Threshold, Forfeited | 1.45 |
Profits Interests Threshold, Vested | 1.44 |
Profits Interests Threshold, Canceled and replaced with restricted stock awards | 1.99 |
Maximum [Member] | |
Profits Interests Threshold, Balance at December 31, 2020 | 2.29 |
Profits Interests Threshold, Granted | 2.13 |
Profits Interests Threshold, Forfeited | 2.29 |
Profits Interests Threshold, Vested | 2.29 |
Profits Interests Threshold, Canceled and replaced with restricted stock awards | $ 2.13 |
Equity-Based Compensation - S_4
Equity-Based Compensation - Summary of Unit Options Activity (Details) | 9 Months Ended |
Sep. 30, 2021$ / sharesshares | |
Share-based Payment Arrangement [Abstract] | |
Number of Options, Outstanding, Beginning balance | shares | 0 |
Number of Options, Unit Grants | shares | 2,292,309 |
Number of Options, Canceled and replaced with stock options | shares | 2,292,309 |
Number of Options, Outstanding, Ending balance | shares | 0 |
Weighted Average Exercise Price per Share, Outstanding, Beginning balance | $ / shares | $ 0 |
Weighted Average Exercise Price per Share, Unit Grants | $ / shares | 4.99 |
Weighted Average Exercise Price per Share, Canceled and replaced with stock options | $ / shares | 4.99 |
Weighted Average Exercise Price per Share, Outstanding, Ending balance | $ / shares | $ 0 |
Weighted Average Remaining Contractual Term, Granted (in years) | 9 years 10 months 20 days |
Weighted Average Remaining Contractual Term, Canceled and replaced with stock options (in years) | 9 years 10 months 20 days |
Equity-Based Compensation - S_5
Equity-Based Compensation - Summary of Components of Equity-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | Jun. 30, 2020 | Sep. 30, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Total equity-based compensation | $ 18,696 | $ 0 | $ 0 | $ 18,978 |
Research and Development | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Total equity-based compensation | 6,635 | 0 | 0 | 6,696 |
General and Administrative | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Total equity-based compensation | $ 12,061 | $ 0 | $ 0 | $ 12,282 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
ICL | ||
Loss Contingencies [Line Items] | ||
Rent expense | $ 0.6 | $ 0.6 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Income Tax Disclosure [Abstract] | ||||
Effective income tax rate | (0.22%) | (0.21%) | (0.21%) | (0.21%) |
Change in uncertain tax position | $ 0 | $ 0 | $ 0 | $ 0 |
Deferred tax assets or liabilities | $ 0 | $ 0 |
Long Term Debt - Additional Inf
Long Term Debt - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Jul. 31, 2021 | Sep. 30, 2020 | Apr. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | |
Debt Instrument [Line Items] | ||||||||
Long-term Debt, Gross | $ 0 | $ 0 | ||||||
Interest Rate On Loan | 20.56% | |||||||
Loss from debt extinguishment | (700,000) | $ 0 | (700,000) | $ 0 | ||||
Interest Expense | ||||||||
Debt Instrument [Line Items] | ||||||||
Loss from debt extinguishment | (700,000) | (700,000) | ||||||
Paycheck Protection Program | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt Instrument, Face Amount | $ 1,300,000 | |||||||
Interest Rate On Loan | 1.00% | |||||||
Debt Prepayment Cost | $ 0 | |||||||
Loan and Security Agreement | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt Instrument, Maturity Date | Sep. 30, 2023 | |||||||
Loan and Security Agreement | Paycheck Protection Program | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt Instrument, Maturity Date | Apr. 30, 2022 | |||||||
Loan and Security Agreement | Avenue Venture Opportunity Fund L.P | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt Instrument, Face Amount | $ 3,000,000 | |||||||
Repayments of additional fees | $ 500,000 | |||||||
Loan and Security Agreement | Avenue Venture Opportunity Fund L.P | Paycheck Protection Program | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt Instrument, Face Amount | $ 1,300,000 | $ 1,300,000 | ||||||
Loan and Security Agreement | Avenue Venture Opportunity Fund L.P | Preferred unit warrant liability | ||||||||
Debt Instrument [Line Items] | ||||||||
Maximum borrowing capacity | $ 10,000,000 | 10,000,000 | 10,000,000 | |||||
Sale of securities | 40,000,000 | |||||||
Issuance of warrants exercisable into preferred units | $ 900,000 | $ 900,000 | $ 900,000 | |||||
Warrant exercise price | $ 7.1471 | $ 7.1471 | $ 7.1471 | |||||
Loan and Security Agreement | Avenue Venture Opportunity Fund L.P | Preferred unit warrant liability | Series E Preferred Units | ||||||||
Debt Instrument [Line Items] | ||||||||
Warrants or Rights Exercised | 118,929 | |||||||
Minimum [Member] | Loan and Security Agreement | Avenue Venture Opportunity Fund L.P | Preferred unit warrant liability | ||||||||
Debt Instrument [Line Items] | ||||||||
Line of credit facility, remaining borrowing capacity | $ 3,000,000 | $ 3,000,000 | $ 3,000,000 | |||||
Maximum [Member] | Loan and Security Agreement | Avenue Venture Opportunity Fund L.P | Preferred unit warrant liability | ||||||||
Debt Instrument [Line Items] | ||||||||
Line of credit facility, current borrowing capacity | $ 7,000,000 | $ 7,000,000 | $ 7,000,000 |
Net Loss Per Share - Schedule o
Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Class A Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2021 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2021 | |
Numerator: | |||||
Net loss | $ (3,142) | $ (2,883) | $ (2,714) | $ (5,350) | $ (3,142) |
Denominator: | |||||
Weighted average Class A common shares outstanding-basic and diluted | 19,437 | 19,437 | |||
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc.-basic and diluted | $ (0.16) | $ (0.16) |
Net Loss Per Share - Schedule_2
Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) shares in Thousands | 9 Months Ended |
Sep. 30, 2021shares | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |
Anti-dilutive securities excluded from computation of diluted net loss per share | 33,673,141 |
Paired Interests [Member] | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |
Anti-dilutive securities excluded from computation of diluted net loss per share | 29,290,391 |
Stock Options [Member] | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |
Anti-dilutive securities excluded from computation of diluted net loss per share | 2,119,524 |
Class A Units of Rani LLC exchangeable for Class A common stock [Member] | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |
Anti-dilutive securities excluded from computation of diluted net loss per share | 1,545,811 |
Restricted Stock Units [Member] | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |
Anti-dilutive securities excluded from computation of diluted net loss per share | 597,500 |
Restricted Stock | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |
Anti-dilutive securities excluded from computation of diluted net loss per share | 119,915 |